title
stringlengths 2
512
| issue
stringlengths 0
29
| pages
stringlengths 1
35
| abstract
stringlengths 0
6.04k
| journal
stringlengths 2
239
| authors
listlengths 0
77
| pubdate
stringlengths 4
10
| pmid
stringlengths 1
7
| mesh_terms
stringlengths 0
2.39k
| publication_types
stringlengths 12
284
| chemical_list
stringlengths 0
920
| keywords
stringlengths 0
1.52k
| doi
stringlengths 0
69
| references
listlengths 0
1.3k
| delete
bool 1
class | languages
stringclasses 95
values | vernacular_title
stringlengths 0
491
| pmc
stringclasses 2
values | other_id
stringlengths 0
44
| medline_ta
stringlengths 2
96
| nlm_unique_id
stringlengths 7
9
| issn_linking
stringlengths 0
9
| country
stringclasses 90
values | grant_ids
listlengths 0
23
| _inserted_at
unknown | _read_from
stringclasses 109
values |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Corrosive esophageal injuries. I. A study of nine cases of concurrent accidental caustic ingestion. | 97(9) | 1060-8 | Treatment of corrosive injuries of the esophagus remains largely unsatisfactory, and severe esophageal burns still frequently result in stricture with accompanying morbidity or death. The nine patients presented here with 3-year follow-up accidentally drank a concentrated alkaline solution. All were teenagers or young adults who drank from the same bottle while at a party. The problems encountered in these patients led us to conclude that all patients with moderate to severe corrosive injury of the esophagus should have assessment of the entire esophagus and stomach at the time of initial assessment. Six patients underwent diagnostic laparotomy and one underwent thoracotomy as well for assessment of his esophageal injuries. Had we followed the traditional approach of esophagoscopy only to the level of the first circumferential burn, more severe and potentially life-threatening injuries would have been missed. Early endoscopic evaluation of the esophagus and stomach remains the standard for diagnosis; however, complete assessment may require laparotomy or thoracotomy. Early resection of necrotic tissue in the esophagus or stomach can lead to increased survival. | The Laryngoscope | [
{
"affiliation": "",
"forename": "J N",
"identifier": "",
"initials": "JN",
"lastname": "Thompson"
}
] | 1987-09 | 3306232 | D000061:Accidents, Home; D000293:Adolescent; D000328:Adult; D002057:Burns, Chemical / Q000209:etiology* / Q000628:therapy; D004940:Esophageal Stenosis / Q000139:chemically induced* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male | D016428:Journal Article; D016454:Review | 10.1288/00005537-198709000-00012 | [] | false | eng | Laryngoscope | 8607378 | 0023-852X | United States | [] | "2024-08-13T08:46:10.495517Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Etiology of the ear disease of the composer Bedrich Smetana]. | 66(6) | 350-3 | As far back as 1964 Professor Dr. H. Feldmann, Director of the Department of Otorhinolaryngology of the Westphalian Wilhelms University of Münster claimed on the basis of his Prague studies that the Czechoslovakian composer Bedrich Smetana suffered from untreated syphilis with which he is said to have infected himself in 1874. The authors of the article presented here are members of the scientific research group of the Museum of Bohemian Music in Prague. On the occasion of the centenary of Smetana's death they were given an opportunity to examine and assess written and factual posthumous documents from Smetana's estate. This research did not yield any pointer towards Smetana's ear disease as being due to a luetic infection. | Laryngologie, Rhinologie, Otologie | [
{
"affiliation": "",
"forename": "O",
"identifier": "",
"initials": "O",
"lastname": "Borík"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Boríková"
}
] | 1987-06 | 3306231 | D003604:Czechoslovakia; D003638:Deafness / Q000209:etiology / Q000266:history*; D005197:Famous Persons; D049672:History, 19th Century; D006801:Humans; D009146:Music / Q000266:history*; D013587:Syphilis / Q000266:history | D019215:Biography; D004740:English Abstract; D016456:Historical Article; D016428:Journal Article | [] | false | ger | Zur Atiologie der Ohrerkrankung des Komponisten Friedrich Smetana. | Laryngol Rhinol Otol (Stuttg) | 7513628 | 0340-1588 | Germany | [] | "2024-08-13T08:46:10.496350Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Large vessel sealing with the argon laser. | 7(3) | 229-35 | This study compared the histology, biochemistry, and tensile strength of laser-welded and sutured canine venotomies, arteriotomies, and arteriovenous fistulas. Twelve animals had bilateral femoral vessels studied, with one repair (control) closed with interrupted 6-0 polypropylene sutures, and the contralateral repair (experimental) welded with the argon laser. Specimens were examined at weekly intervals from 1 to 4 weeks (four animals for each type of repair), and were evaluated histologically by hematoxylin and eosin, elastin, and trichrome stains; biochemically by the formation of [3H]hydroxyproline as an index of collagen synthesis; and mechanically by tensile strength determinations. At removal, all experimental closures were patent without hematomas, aneurysms, or luminal dilatation. Histologic and biochemical examination and tensile strength determinations suggest that laser welding may be an alternative to sutures for repair of large-diameter venotomies, arteriotomies, and arteriovenous fistulas, as healing is comparable to that seen with suture repairs up to 4 weeks postoperatively. | Lasers in surgery and medicine | [
{
"affiliation": "",
"forename": "R A",
"identifier": "",
"initials": "RA",
"lastname": "White"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Kopchok"
},
{
"affiliation": "",
"forename": "C",
"identifier": "",
"initials": "C",
"lastname": "Donayre"
},
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Lyons"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "White"
},
{
"affiliation": "",
"forename": "S R",
"identifier": "",
"initials": "SR",
"lastname": "Klein"
},
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Pizzurro"
},
{
"affiliation": "",
"forename": "R P",
"identifier": "",
"initials": "RP",
"lastname": "Abergel"
},
{
"affiliation": "",
"forename": "R M",
"identifier": "",
"initials": "RM",
"lastname": "Dwyer"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Uitto"
}
] | 1987 | 3306233 | D000818:Animals; D001166:Arteriovenous Shunt, Surgical / Q000379:methods*; D004285:Dogs; D053685:Laser Therapy; D013536:Suture Techniques; D013718:Tensile Strength; D014656:Vascular Surgical Procedures / Q000379:methods* | D003160:Comparative Study; D016428:Journal Article; D013487:Research Support, U.S. Gov't, P.H.S. | 10.1002/lsm.1900070305 | [] | false | eng | Lasers Surg Med | 8007168 | 0196-8092 | United States | [
{
"agency": "NIADDK NIH HHS",
"country": "United States",
"grant_acronym": "AM",
"grant_id": "AM-28450"
},
{
"agency": "NIGMS NIH HHS",
"country": "United States",
"grant_acronym": "GM",
"grant_id": "GM-28833"
},
{
"agency": "NHLBI NIH HHS",
"country": "United States",
"grant_acronym": "HL",
"grant_id": "HL-32622"
}
] | "2024-08-13T08:46:10.497455Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Pulmonary procedures assisted by optosurgical and electrosurgical devices: comparison of damage potential. | 7(3) | 263-72 | Electrosurgical devices have been used widely in thoracic surgery to assist in dissection and to reduce hemorrhage. Recent experimental data have shown that lasers may be used to resect and control small air leaks while conserving normally functioning lung. This investigation quantitates the amount of damage produced by the electrosurgical unit (ESU), the carbon dioxide laser (CO2), and the neodymium: YAG laser (YAG) compared to standard suture (SU) techniques. Six dogs were anesthetized, intubated, and ventilated. The left chest was opened and the lower lobe exposed, where four sets of lesions were created using each device. All lesions were visually similar to those lesions that would be created for sealing at the time of a pulmonary resection. The lesions were harvested immediately following wounding as well as at 1, 3, and 6 week intervals. They were examined histologically and ranked from least to most damage produced at each interval. A grading system (0-4+) was also devised to compare the injury to simultaneously harvested normal lung. Immediately following injury, histologic ranking was: CO2 (2+), suture (2+), ESU (3+), YAG (4+). By 6 weeks, the suture damage had become minimal and the ranking was: suture (1+), CO2 (2+), YAG (4+), ESU (4+). The ESU consistently produced more extensive damage than any other device. It appears that the most suitable long-term adjunctive devices to assist in pulmonary surgery are suture and the CO2 laser. The YAG laser may have specific indications in circumstances when significant blood loss may be encountered. ESU usage should be minimized when attempting to preserve functioning lung tissue. | Lasers in surgery and medicine | [
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "LoCicero"
},
{
"affiliation": "",
"forename": "J W",
"identifier": "",
"initials": "JW",
"lastname": "Frederiksen"
},
{
"affiliation": "",
"forename": "R S",
"identifier": "",
"initials": "RS",
"lastname": "Hartz"
},
{
"affiliation": "",
"forename": "L L",
"identifier": "",
"initials": "LL",
"lastname": "Michaelis"
}
] | 1987 | 3306234 | D000818:Animals; D004285:Dogs; D004598:Electrosurgery / Q000009:adverse effects*; D053685:Laser Therapy / Q000009:adverse effects*; D008168:Lung / Q000601:surgery*; D055370:Lung Injury; D012306:Risk; D013536:Suture Techniques; D014945:Wound Healing | D003160:Comparative Study; D016428:Journal Article | 10.1002/lsm.1900070310 | [] | false | eng | Lasers Surg Med | 8007168 | 0196-8092 | United States | [] | "2024-08-13T08:46:10.499448Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Interleukin-1 and osteoarthritis. | 41(10) | 1187-98 | Il-1, a multifunctional monokine, can stimulate both synoviocytes and articular chondrocytes to release neutral proteases and prostaglandin E2. It is also capable of promoting bone resorption. Therefore, this molecule (or family of molecules) is likely to play an important role in the mechanism of articular cartilage destruction that occurs in degenerative arthropathies. The synovial tissue itself can produce Il-1 (Catabolin) in some conditions, such as a slight traumatism, so that the presence of local inflammation is not necessary for "Il-1-cartilage" interaction to occur. Fundamental macromolecules of cartilage (collagens, proteoglycans) exert a stimulatory effect on Il-1 production, either as such or in the form of immune complexes. Some activated complement fractions (C3a and C5a) may also be actively involved. Studies on the mechanisms which regulate Il-1 synthesis and release, as well as investigations on the response of target cells to Il-1, are presently fascinating goals that could lead to new strategies in therapeutic research. | Life sciences | [
{
"affiliation": "",
"forename": "J P",
"identifier": "",
"initials": "JP",
"lastname": "Pujol"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Loyau"
}
] | 1987-09-07 | 3306235 | D000818:Animals; D002358:Cartilage, Articular / Q000166:cytology / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology / Q000502:physiology*; D010003:Osteoarthritis / Q000276:immunology / Q000503:physiopathology* | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't; D016454:Review | D007375:Interleukin-1 | 10.1016/0024-3205(87)90196-2 | [] | false | eng | Life Sci | 0375521 | 0024-3205 | Netherlands | [] | "2024-08-13T08:46:10.500318Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Saturable transport of peptides across the blood-brain barrier. | 41(11) | 1319-38 | Peptides can be transported across the blood-brain barrier by saturable transport systems. One system, characterized with radioactively labeled Tyr-MIF-1 (Tyr-Pro-Leu-Gly-amide), is specific for some of the small peptides with an N-terminal tyrosine, including Tyr-MIF-1, the enkephalins, beta-casomorphin, and dynorphin (1-8). Another separate system transports vasopressin-like peptides. The choroid plexus has at least one system distinguishable from those above that is capable of uptake and possibly transport of opiate-like peptides. The possibility of saturable transport of other peptides has been investigated to a varying degree. Specificity, stereo-specificity, saturability, allosteric regulation, modulation by physiologic and pharmacologic manipulations, and noncompetitive inhibition have been demonstrated to occur in peptide transport systems and suggest a role for them in physiology and disease. | Life sciences | [
{
"affiliation": "",
"forename": "W A",
"identifier": "",
"initials": "WA",
"lastname": "Banks"
},
{
"affiliation": "",
"forename": "A J",
"identifier": "",
"initials": "AJ",
"lastname": "Kastin"
}
] | 1987-09-14 | 3306236 | D000375:Aging; D000535:Aluminum / Q000633:toxicity; D000818:Animals; D001692:Biological Transport; D001812:Blood-Brain Barrier; D002940:Circadian Rhythm; D006801:Humans; D010455:Peptides / Q000378:metabolism*; D013312:Stress, Physiological / Q000503:physiopathology | D016428:Journal Article; D013486:Research Support, U.S. Gov't, Non-P.H.S.; D016454:Review | D010455:Peptides; D000535:Aluminum | 10.1016/0024-3205(87)90606-0 | [] | false | eng | Life Sci | 0375521 | 0024-3205 | Netherlands | [] | "2024-08-13T08:46:10.501182Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Plasma bilirubin pigments in health and disease. | 9(5) | 391-404 | Molecular aspects of medicine | [
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Fevery"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Muraca"
},
{
"affiliation": "",
"forename": "V",
"identifier": "",
"initials": "V",
"lastname": "Mesa"
},
{
"affiliation": "",
"forename": "W",
"identifier": "",
"initials": "W",
"lastname": "Van Steenbergen"
},
{
"affiliation": "",
"forename": "N",
"identifier": "",
"initials": "N",
"lastname": "Blanckaert"
}
] | 1987 | 3306238 | D000818:Animals; D001663:Bilirubin / Q000097:blood*; D006801:Humans; D010860:Pigments, Biological / Q000097:blood* | D003160:Comparative Study; D016428:Journal Article; D016454:Review | D010860:Pigments, Biological; D001663:Bilirubin | 10.1016/0098-2997(87)90005-7 | [] | false | eng | Mol Aspects Med | 7603128 | 0098-2997 | England | [] | "2024-08-13T08:46:10.502138Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
The hepatocellular uptake of bilirubin: current concepts and controversies. | 9(5) | 405-28 | Molecular aspects of medicine | [
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Sorrentino"
},
{
"affiliation": "",
"forename": "W",
"identifier": "",
"initials": "W",
"lastname": "Stremmel"
},
{
"affiliation": "",
"forename": "P D",
"identifier": "",
"initials": "PD",
"lastname": "Berk"
}
] | 1987 | 3306239 | D000818:Animals; D001663:Bilirubin / Q000378:metabolism*; D006801:Humans; D008099:Liver / Q000166:cytology / Q000378:metabolism* | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't; D013487:Research Support, U.S. Gov't, P.H.S.; D016454:Review | D001663:Bilirubin | 10.1016/0098-2997(87)90006-9 | [] | false | eng | Mol Aspects Med | 7603128 | 0098-2997 | England | [
{
"agency": "NIADDK NIH HHS",
"country": "United States",
"grant_acronym": "AM",
"grant_id": "AM-26438"
}
] | "2024-08-13T08:46:10.502902Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Metabolism in humans of cis-12,trans-15-octadecadienoic acid relative to palmitic, stearic, oleic and linoleic acids. | 22(7) | 495-504 | Mixtures of triglycerides containing deuterium-labeled hexadecanoic acid (16:0), octadecanoic acid (18:0), cis-9-octadecenoic acid (9c-18:1), cis-9,cis-12-octadecadienoic acid (9c, 12c-18:2) and cis-12,trans-15-octadecadienoic acid (12c,15t-18:2) were fed to two young-adult males. Plasma lipid classes were isolated from samples collected periodically over 48 hr. Incorporation and turnover of the deuterium-labeled fats in plasma lipids were followed by gas chromatography-mass spectrometry (GC-MS) analysis of the methyl ester derivatives. Absorption of the deuterated fats was followed by GC-MS analysis of chylomicron triglycerides isolated by ultracentrifugation. Results were the following: (i) endogenous fat contributed about 40% of the total fat incorporated into chylomicron triglycerides; (ii) elongation, desaturation and chain-shortened products from the deuterated fats were not detected; (iii) the polyunsaturated isomer 12c,15t-18:2 was metabolically more similar to saturated and 9c-18:1 fatty acids than to 9c,12c-18:2; (iv) relative incorporation of 9c,12c-18:2 into phospholipids did not increase proportionally with an increase of 9c,12c-18:2 in the mixture of deuterated fats fed; (v) absorption of 16:0, 18:0, 9c-18:1, 9c,12c-18:2 and 12c,15t-18:2 were similar; and (vi) data for the 1- and 2-acyl positions of phosphatidylcholine and for cholesteryl ester fractions reflected the known high specificity of phosphatidylcholine acyltransferase and lecithin:cholesteryl acyltransferase for 9c,12c-18:2. These results illustrate that incorporation of dietary fatty acids into human plasma lipid classes is selectively controlled and that incorporation of dietary 9c,12c-18:2 is limited. These results suggest that nutritional benefits of diets high in 9c,12c-18:2 may be of little value to normal subjects and that the 12c,15t-18:2 isomer in hydrogenated fat is not a nutritional liability at the present dietary level. | Lipids | [
{
"affiliation": "",
"forename": "E A",
"identifier": "",
"initials": "EA",
"lastname": "Emken"
},
{
"affiliation": "",
"forename": "W K",
"identifier": "",
"initials": "WK",
"lastname": "Rohwedder"
},
{
"affiliation": "",
"forename": "R O",
"identifier": "",
"initials": "RO",
"lastname": "Adlof"
},
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Rakoff"
},
{
"affiliation": "",
"forename": "R M",
"identifier": "",
"initials": "RM",
"lastname": "Gulley"
}
] | 1987-07 | 3306237 | D000328:Adult; D002788:Cholesterol Esters / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D003903:Deuterium; D004041:Dietary Fats / Q000378:metabolism*; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000378:metabolism*; D008297:Male; D019301:Oleic Acid; D009829:Oleic Acids / Q000378:metabolism*; D019308:Palmitic Acid; D010169:Palmitic Acids / Q000378:metabolism*; D010743:Phospholipids / Q000097:blood; D011865:Radioisotope Dilution Technique; D013229:Stearic Acids / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism* | D016428:Journal Article | D002788:Cholesterol Esters; D002914:Chylomicrons; D004041:Dietary Fats; D005231:Fatty Acids, Unsaturated; D008041:Linoleic Acids; D009829:Oleic Acids; D010169:Palmitic Acids; D010743:Phospholipids; D013229:Stearic Acids; D014280:Triglycerides; C027369:octadecadienoic acid; D019301:Oleic Acid; D019308:Palmitic Acid; C031183:stearic acid; D019787:Linoleic Acid; D003903:Deuterium | 10.1007/BF02540365 | [
{
"citation": "J Lipid Res. 1963 Jul;4:312-21",
"pmid": "14168169"
},
{
"citation": "J Chromatogr. 1973 Jul 18;82(1):15-30",
"pmid": "4269194"
},
{
"citation": "J Biol Chem. 1969 Dec 10;244(23):6514-9",
"pmid": "5354965"
},
{
"citation": "Annu Rev Nutr. 1984;4:339-76",
"pmid": "6432011"
},
{
"citation": "Biochemistry. 1962 Sep;1:804-10",
"pmid": "13974345"
},
{
"citation": "J Lipid Res. 1983 Jan;24(1):34-46",
"pmid": "6833880"
},
{
"citation": "Lipids. 1980 Oct;15(10):864-71",
"pmid": "7442476"
},
{
"citation": "Am J Clin Nutr. 1979 Dec;32(12):2390-9",
"pmid": "506962"
},
{
"citation": "Biochim Biophys Acta. 1985 Sep 11;836(2):233-45",
"pmid": "4027264"
},
{
"citation": "J Nutr. 1979 Oct;109(10):1682-7",
"pmid": "490206"
},
{
"citation": "J Nutr. 1985 Oct;115(10):1248-58",
"pmid": "4045568"
},
{
"citation": "Am J Clin Nutr. 1981 Apr;34(4):568-80",
"pmid": "7223707"
},
{
"citation": "Metabolism. 1979 May;28(5):575-83",
"pmid": "449699"
},
{
"citation": "J Biol Chem. 1972 Mar 10;247(5):1414-23",
"pmid": "5012315"
},
{
"citation": "J Lipid Res. 1967 Nov;8(6):676-81",
"pmid": "6057496"
},
{
"citation": "Am J Physiol. 1985 Feb;248(2 Pt 1):G164-9",
"pmid": "3970197"
},
{
"citation": "Lipids. 1986 Sep;21(9):589-95",
"pmid": "3762332"
},
{
"citation": "Lipids. 1966 Mar;1(2):89-97",
"pmid": "17805659"
},
{
"citation": "J Biol Chem. 1957 May;226(1):497-509",
"pmid": "13428781"
},
{
"citation": "Trans Am Soc Artif Intern Organs. 1975;21:473-8",
"pmid": "1146020"
},
{
"citation": "Lipids. 1984 Dec;19(12):942-51",
"pmid": "6527613"
},
{
"citation": "Lipids. 1986 Sep;21(9):543-7",
"pmid": "3762326"
},
{
"citation": "J Chromatogr. 1973 May 30;80(1):133-6",
"pmid": "4708400"
},
{
"citation": "Lipids. 1986 Feb;21(2):121-6",
"pmid": "3959773"
}
] | false | eng | Lipids | 0060450 | 0024-4201 | United States | [] | "2024-08-13T08:46:10.505502Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Genetic deficiency of bilirubin glucuronidation in rats and humans. | 9(5) | 429-55 | Molecular aspects of medicine | [
{
"affiliation": "",
"forename": "B",
"identifier": "",
"initials": "B",
"lastname": "Burchell"
},
{
"affiliation": "",
"forename": "M W",
"identifier": "",
"initials": "MW",
"lastname": "Coughtrie"
},
{
"affiliation": "",
"forename": "M R",
"identifier": "",
"initials": "MR",
"lastname": "Jackson"
},
{
"affiliation": "",
"forename": "S R",
"identifier": "",
"initials": "SR",
"lastname": "Shepherd"
},
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Harding"
},
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Hume"
}
] | 1987 | 3306240 | D000818:Animals; D001663:Bilirubin / Q000172:deficiency*; D005965:Glucuronates / Q000172:deficiency*; D006801:Humans; D007565:Jaundice / Q000151:congenital*; D051381:Rats; D013045:Species Specificity | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't; D016454:Review | D005965:Glucuronates; D001663:Bilirubin | 10.1016/0098-2997(87)90007-0 | [] | false | eng | Mol Aspects Med | 7603128 | 0098-2997 | England | [] | "2024-08-13T08:46:10.506546Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Phototherapy and the chemistry of bilirubin. | 9(5) | 457-71 | Molecular aspects of medicine | [
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Bonnett"
},
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Ioannou"
}
] | 1987 | 3306241 | D001663:Bilirubin / Q000502:physiology*; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D010789:Phototherapy | D016428:Journal Article; D016454:Review | D001663:Bilirubin | 10.1016/0098-2997(87)90008-2 | [] | false | eng | Mol Aspects Med | 7603128 | 0098-2997 | England | [] | "2024-08-13T08:46:10.507450Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Crigler-Najjar syndrome types I and II. Clinical experience--King's College Hospital 1972-1978. Phenobarbitone, phototherapy and liver transplantation. | 9(5) | 473-82 | Molecular aspects of medicine | [
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Pett"
},
{
"affiliation": "",
"forename": "A P",
"identifier": "",
"initials": "AP",
"lastname": "Mowat"
}
] | 1987 | 3306242 | D002648:Child; D002675:Child, Preschool; D003414:Crigler-Najjar Syndrome / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006801:Humans; D006933:Hyperbilirubinemia, Hereditary / Q000628:therapy*; D007223:Infant; D016031:Liver Transplantation; D008297:Male; D010634:Phenobarbital / Q000627:therapeutic use*; D010789:Phototherapy; D013577:Syndrome | D016428:Journal Article | D010634:Phenobarbital | 10.1016/0098-2997(87)90009-4 | [] | false | eng | Mol Aspects Med | 7603128 | 0098-2997 | England | [] | "2024-08-13T08:46:10.508281Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Bilirubin metabolism in cholestasis. | 9(5) | 483-98 | Molecular aspects of medicine | [
{
"affiliation": "",
"forename": "B H",
"identifier": "",
"initials": "BH",
"lastname": "Billing"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Kountouras"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Burmicky"
}
] | 1987 | 3306243 | D001663:Bilirubin / Q000378:metabolism*; D002779:Cholestasis / Q000378:metabolism*; D006801:Humans | D016428:Journal Article; D016454:Review | D001663:Bilirubin | 10.1016/0098-2997(87)90010-0 | [] | false | eng | Mol Aspects Med | 7603128 | 0098-2997 | England | [] | "2024-08-13T08:46:10.508963Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
The active roles of cells of the blood vessel wall in health and disease. | 9(6) | 499-567 | Molecular aspects of medicine | [
{
"affiliation": "",
"forename": "P",
"identifier": "",
"initials": "P",
"lastname": "Libby"
}
] | 1987 | 3306244 | D000818:Animals; D001161:Arteriosclerosis / Q000503:physiopathology*; D001808:Blood Vessels / Q000502:physiology* / Q000503:physiopathology; D004727:Endothelium / Q000502:physiology* / Q000503:physiopathology; D006487:Hemostasis; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000502:physiology* / Q000503:physiopathology | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't; D013486:Research Support, U.S. Gov't, Non-P.H.S.; D013487:Research Support, U.S. Gov't, P.H.S.; D016454:Review | 10.1016/0098-2997(87)90003-3 | [] | false | eng | Mol Aspects Med | 7603128 | 0098-2997 | England | [
{
"agency": "NHLBI NIH HHS",
"country": "United States",
"grant_acronym": "HL",
"grant_id": "HL-34636"
}
] | "2024-08-13T08:46:10.509621Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
History of contraception in Baltimore. | 36(7) | 597-601 | Maryland medical journal (Baltimore, Md. : 1985) | [
{
"affiliation": "",
"forename": "D F",
"identifier": "",
"initials": "DF",
"lastname": "Kaltreider"
}
] | 1987-07 | 3306245 | D003267:Contraception / Q000266:history*; D005193:Family Planning Services / Q000266:history; D049673:History, 20th Century; D006801:Humans; D008396:Maryland | D019215:Biography; D016456:Historical Article; D016428:Journal Article; D019477:Portrait | [] | false | eng | Md Med J | 8506985 | 0886-0572 | United States | [] | "2024-08-13T08:46:10.511385Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
[Psychological evaluation of patients with Peyronie's disease]. | 28(1) | 9-11 | Minerva psichiatrica | [
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Caddeo"
},
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Carpineta"
},
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Vacilotto"
},
{
"affiliation": "",
"forename": "F",
"identifier": "",
"initials": "F",
"lastname": "Sasso"
},
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Destito"
},
{
"affiliation": "",
"forename": "E",
"identifier": "",
"initials": "E",
"lastname": "Alcini"
}
] | 1987 | 3306246 | D000328:Adult; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000523:psychology*; D011386:Projective Techniques | D004740:English Abstract; D016428:Journal Article | [] | false | ita | Valutazione psicologica in pazienti affetti da malattia di La Peyronie. | Minerva Psichiatr | 7707981 | 0374-9320 | Italy | [] | "2024-08-13T08:46:10.512099Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
Pathogenesis of adhesion formation/reformation: application to reproductive pelvic surgery. | 8(2) | 103-7 | Pelvic adhesions are a major contributing factor to infertility in women with tubal peritoneal disease. Surgical treatment of such adhesions often does not resolve their presence. Such postoperative adhesion formation occurs despite the use of microsurgical techniques in a wide variety of surgical adjuvants. The process of adhesion formation represents a variation of the normal healing process of the peritoneum. However, rather than normal mesothelial healing, the fibrinous mass resulting from the peritoneal defect is infiltrated by fibroblasts with subsequent adhesion formation. A description of the pathophysiology of this process is described. The current understanding of the pathologic/pathophysiologic interaction of the surgical adjuvants with this process is described. | Microsurgery | [
{
"affiliation": "",
"forename": "M P",
"identifier": "",
"initials": "MP",
"lastname": "Diamond"
},
{
"affiliation": "",
"forename": "A H",
"identifier": "",
"initials": "AH",
"lastname": "Decherney"
}
] | 1987 | 3306252 | D005260:Female; D005836:Genitalia, Female / Q000601:surgery*; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D010388:Pelvis; D011183:Postoperative Complications / Q000517:prevention & control; D000267:Tissue Adhesions / Q000517:prevention & control | D016428:Journal Article; D016454:Review | 10.1002/micr.1920080215 | [] | false | eng | Microsurgery | 8309230 | 0738-1085 | United States | [] | "2024-08-13T08:46:10.512757Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Microsurgical reconstruction of congenital tubal anomalies. | 8(2) | 68-77 | Significant numbers of infertile women have congenital anomalies or anatomical distortion of the fimbrial-gonadal mechanism in their otherwise healthy oviducts. The diagnosis and surgical treatment of multiple congenital accessory tubal ostia, the elongated fimbria-ovarica syndrome, and management of paratubal cysts is described. Microsurgical correction of these defects was followed by term pregnancies in 46%, 57% and 28% of the three entities respectively and this data indicates that significant numbers of women with these defects may be helped by microsurgery. Failure to recognize these abnormalities may otherwise result in patients being diagnosed as idiopathic infertility, a decision which may exclude them from the possibility of undergoing a successful form of microsurgical treatment. | Microsurgery | [
{
"affiliation": "",
"forename": "B M",
"identifier": "",
"initials": "BM",
"lastname": "Cohen"
}
] | 1987 | 3306253 | D003560:Cysts / Q000151:congenital; D005187:Fallopian Tubes / Q000002:abnormalities* / Q000601:surgery; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D008866:Microsurgery / Q000379:methods; D013536:Suture Techniques | D016428:Journal Article | 10.1002/micr.1920080209 | [] | false | eng | Microsurgery | 8309230 | 0738-1085 | United States | [] | "2024-08-13T08:46:10.513594Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Comparison between tubouterine implantation and tubouterine anastomosis for repair of cornual occlusion. | 8(2) | 78-82 | Forty-four patients with partial or complete cornual occlusion of their tubes had undergone microsurgical repair in the form of either tubouterine implantation or tubouterine anastomosis. Eighteen of these patients had undergone the implantation procedure and 26 the anastomosis procedure. None of the patients in the implantation group had previous tubal sterilization, while in the anastomosis group 16 had tubal cauterization and 10 had other causes blocking the cornual end of their tubes. The patency rate in the implantation group was 70% and the pregnancy rate was 39%, while in the anastomosis group the rates were 94% and 69%, respectively. It is concluded that, when feasible, tubouterine anastomosis should be the procedure of choice for the repair of the cornual occlusion of the tube irrespective of the cause of obstruction. | Microsurgery | [
{
"affiliation": "",
"forename": "J A",
"identifier": "",
"initials": "JA",
"lastname": "Fayez"
}
] | 1987 | 3306254 | D005184:Fallopian Tube Diseases / Q000601:surgery*; D005186:Fallopian Tube Patency Tests; D005187:Fallopian Tubes / Q000601:surgery*; D005260:Female; D006801:Humans; D007239:Infections; D007247:Infertility, Female / Q000628:therapy; D008866:Microsurgery / Q000379:methods; D013243:Sterilization Reversal / Q000379:methods; D013536:Suture Techniques; D014599:Uterus / Q000601:surgery* | D016428:Journal Article | 10.1002/micr.1920080210 | [] | false | eng | Microsurgery | 8309230 | 0738-1085 | United States | [] | "2024-08-13T08:46:10.514344Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Changes in carbohydrate and lipid metabolism in obesity]. | 46(6) | 677-85 | Medicina | [
{
"affiliation": "",
"forename": "S M",
"identifier": "",
"initials": "SM",
"lastname": "Actis Dato"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Pittana"
},
{
"affiliation": "",
"forename": "J E",
"identifier": "",
"initials": "JE",
"lastname": "Costa Gil"
},
{
"affiliation": "",
"forename": "R E",
"identifier": "",
"initials": "RE",
"lastname": "Nieto"
}
] | 1986 | 3306255 | D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002241:Carbohydrates / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D014280:Triglycerides / Q000097:blood | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't | D001786:Blood Glucose; D002241:Carbohydrates; D008076:Cholesterol, HDL; D006442:Glycated Hemoglobin A; D007328:Insulin; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol | [] | false | spa | Alteraciones del metabolismo de los hidratos de carbono y lípidos en la obesidad. | Medicina (B Aires) | 0204271 | 0025-7680 | Argentina | [] | "2024-08-13T08:46:10.515346Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Increase in the size of an hepatic amebic abscess treated with metronidazole: value of immunologic surveillance with the ELIFA method]. | 47(2) | 193-5 | The authors report a case of amoebic liver abscess regularly increasing in size for a period of 20 days (iterative controls by echography), in spite of a metronidazole treatment. Immunological studies by the ELIFA method, on the successive sera of the patient, show IgG, IgM, IgE and IgA antibodies within one particular precipitating system; the specific IgA disappeared after surgical drainage of the abscess. | Medecine tropicale : revue du Corps de sante colonial | [
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Poirriez"
},
{
"affiliation": "",
"forename": "J B",
"identifier": "",
"initials": "JB",
"lastname": "Flament"
},
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Thoannes"
},
{
"affiliation": "",
"forename": "J M",
"identifier": "",
"initials": "JM",
"lastname": "Pinon"
}
] | 1987 | 3306251 | D006801:Humans; D007124:Immunoenzyme Techniques; D008101:Liver Abscess, Amebic / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use* | D002363:Case Reports; D004740:English Abstract; D016428:Journal Article | D008795:Metronidazole | [] | false | fre | Augmentation de volume d'un abcès amibien hépatique traité par le métronidazole: intérêt de la surveillance immunologique par la méthode ELIFA. | Med Trop (Mars) | 8710146 | 0025-682X | France | [] | "2024-08-13T08:46:10.517266Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
[Hypothermia, shock and coagulation disorders in a kidney transplant]. | 46(6) | 729-38 | Medicina | [] | 1986 | 3306257 | D000328:Adult; D001778:Blood Coagulation Disorders / Q000209:etiology; D005260:Female; D006801:Humans; D007035:Hypothermia / Q000209:etiology*; D002534:Hypoxia, Brain / Q000209:etiology*; D016030:Kidney Transplantation; D008099:Liver / Q000473:pathology; D011183:Postoperative Complications / Q000209:etiology*; D018805:Sepsis / Q000150:complications | D002363:Case Reports; D016428:Journal Article | [] | false | spa | Hipotermia, shock y alteraciones de la coagulación en un transplante renal. | Medicina (B Aires) | 0204271 | 0025-7680 | Argentina | [] | "2024-08-13T08:46:10.517916Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
[Genetic component of the immune response to Mycobacterium leprae in healthy subjects]. | 46(6) | 713-8 | Medicina | [
{
"affiliation": "",
"forename": "O A",
"identifier": "",
"initials": "OA",
"lastname": "Bottasso"
},
{
"affiliation": "",
"forename": "L",
"identifier": "",
"initials": "L",
"lastname": "Hinrichsen"
},
{
"affiliation": "",
"forename": "J C",
"identifier": "",
"initials": "JC",
"lastname": "Morini"
},
{
"affiliation": "",
"forename": "S L",
"identifier": "",
"initials": "SL",
"lastname": "Rabasa"
}
] | 1986 | 3306256 | D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000235:genetics*; D007111:Immunity, Cellular; D007916:Lepromin / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000276:immunology* | D004740:English Abstract; D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't | D007916:Lepromin | [] | false | spa | El componente genético de la respuesta inmune al Mycobacterium leprae en individuos sanos. | Medicina (B Aires) | 0204271 | 0025-7680 | Argentina | [] | "2024-08-13T08:46:10.518618Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Treatment of hematosis disorders in chronic obstructive bronchitis with almitrine bismesylate]. | 46(6) | 739-41 | Medicina | [
{
"affiliation": "",
"forename": "L J",
"identifier": "",
"initials": "LJ",
"lastname": "González Montaner"
}
] | 1986 | 3306258 | D015765:Almitrine; D000818:Animals; D001784:Blood Gas Analysis; D002986:Clinical Trials as Topic; D004285:Dogs; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D012131:Respiratory Insufficiency / Q000188:drug therapy*; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects | D016430:Clinical Trial; D016428:Journal Article | D010879:Piperazines; D015765:Almitrine | [] | false | spa | Tratamiento de los disturbios de la hematosis en la bronquitis crónica obstructiva con bismesilato de almitrina. | Medicina (B Aires) | 0204271 | 0025-7680 | Argentina | [] | "2024-08-13T08:46:10.519527Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Epidemiological peculiarities of pernicious attacks by Plasmodium falciparum in the context of a malaria epidemic. Vanuatu, 1975-1985]. | 47(2) | 125-31 | A retrospective study of the cerebral malaria cases occurred in five hospitals from 1975 to 1985 was conducted in the Republic of Vanuatu (ex-New Hébrides). The situation in this archipelago since 1980 of the epidemic type, with a dramatic increase in Plasmodium falciparum incidence and prevalence. A considerable increase of the incidence of cerebral malaria has been evidenced in the whole group, in parallel with that of the P. falciparum incidence. Moreover, an unusual age distribution has been noted, with a maximum incidence in the adult age group, and a minimum in the infant one. The most evident misleading factors have been excluded, and possible explanations for this particular distribution are discussed. Finally, this increase in cerebral malaria incidence did not appear to be directly due to the concomitant spread of chloroquine resistant P. falciparum over the country, but rather to the resulting increasing incidence of this parasite. | Medecine tropicale : revue du Corps de sante colonial | [
{
"affiliation": "",
"forename": "P",
"identifier": "",
"initials": "P",
"lastname": "Bastien"
}
] | 1987 | 3306247 | D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008288:Malaria / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum; D012189:Retrospective Studies; D009514:Vanuatu | D004740:English Abstract; D016428:Journal Article | [] | false | fre | Particularités épidémiologiques des accès pernicieux à Plasmodium falciparum dans un contexte d'épidémie palustre. Vanuatu, 1975-1985. | Med Trop (Mars) | 8710146 | 0025-682X | France | [] | "2024-08-13T08:46:10.520260Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Small-airways disease in recipients of allogeneic bone marrow transplants. An analysis of 11 cases and a review of the literature. | 66(5) | 327-40 | In a retrospective review of 116 consecutive allogeneic bone marrow transplants (BMT), severe obstructive airways disease was identified in 11 patients. Lung pathology demonstrated bronchiolitis in 9 patients and physiologic studies showed small-airways disease consistent with bronchiolitis in the other 2. None of the 5 patients with associated infection survived, while 3 of the 6 patients without an identified pathogen stabilized or improved. Analysis of the 11 cases presented and all 25 cases reported in the literature (1982 to 1985) supports the conclusion that graft-versus-host disease is a major risk factor for bronchiolitis in BMT recipients. Among the proposed mechanisms for the development of bronchiolitis after allogeneic BMT, the 2 most likely are graft-versus-host disease directly causing bronchiolitis, and increased immunosuppressive therapy given for graft-versus-host disease predisposing to viral bronchiolitis. The available evidence would suggest that it is prudent to obtain serial pulmonary function tests even in asymptomatic patients post-BMT, and particularly in those with chronic graft-versus-host disease, in the hope that early detection will allow for early intervention that will arrest or reverse the progression of the obstructive airways disease. | Medicine | [
{
"affiliation": "",
"forename": "C K",
"identifier": "",
"initials": "CK",
"lastname": "Chan"
},
{
"affiliation": "",
"forename": "R H",
"identifier": "",
"initials": "RH",
"lastname": "Hyland"
},
{
"affiliation": "",
"forename": "M A",
"identifier": "",
"initials": "MA",
"lastname": "Hutcheon"
},
{
"affiliation": "",
"forename": "M D",
"identifier": "",
"initials": "MD",
"lastname": "Minden"
},
{
"affiliation": "",
"forename": "M A",
"identifier": "",
"initials": "MA",
"lastname": "Alexander"
},
{
"affiliation": "",
"forename": "A E",
"identifier": "",
"initials": "AE",
"lastname": "Kossakowska"
},
{
"affiliation": "",
"forename": "S J",
"identifier": "",
"initials": "SJ",
"lastname": "Urbanski"
},
{
"affiliation": "",
"forename": "G M",
"identifier": "",
"initials": "GM",
"lastname": "Fyles"
},
{
"affiliation": "",
"forename": "I M",
"identifier": "",
"initials": "IM",
"lastname": "Fraser"
},
{
"affiliation": "",
"forename": "J E",
"identifier": "",
"initials": "JE",
"lastname": "Curtis"
}
] | 1987-09 | 3306259 | D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D016026:Bone Marrow Transplantation; D001990:Bronchiolitis, Viral / Q000209:etiology* / Q000401:mortality / Q000473:pathology; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality* / Q000473:pathology; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008171:Lung Diseases / Q000209:etiology / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011379:Prognosis | D002363:Case Reports; D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't | 10.1097/00005792-198709000-00001 | [] | false | eng | Medicine (Baltimore) | 2985248R | 0025-7974 | United States | [] | "2024-08-13T08:46:10.521569Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Resistance of Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde region (Senegal)]. | 47(2) | 171-5 | Since 1983, primary resistance of M. leprae to DDS and rifampicin has been evaluated in new cases of lepromatous leprosy observed in the Cap-Verde region in Senegal. Out of the 13 strains isolated, 10 (77%) have been found resistant to DDS, 7 at low level, 2 at intermediate level, 1 at high level; all of them have been found sensible to rifampicin. Similar results have been obtained with 57 strains isolated from patients not yet treated coming from different geographical areas, seeing that 37, i.e. 65%, were resistant to DDS, 27 at low level, 5 at intermediate level and 5 at high level; all of them were sensible to rifampicin. Level of resistance to DDS is very different in case of acquired resistance. In 69 lepromatous patients treated for more than 5 years and showing a relapse, M. leprae was 62 times, i.e. 90%, resistant to DDS, 6 times at low level, 21 at intermediate level and 35 at high level; in addition, 13 times M. leprae was resistant to rifampicin. In order to avoid and to solve problems set by resistance of M. leprae to antibiotics, strict application of polychemotherapy of leprosy is compulsory. | Medecine tropicale : revue du Corps de sante colonial | [
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Grosset"
},
{
"affiliation": "",
"forename": "C C",
"identifier": "",
"initials": "CC",
"lastname": "Guelpa-Lauras"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Millan"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Bodian"
},
{
"affiliation": "",
"forename": "E",
"identifier": "",
"initials": "E",
"lastname": "Perani"
}
] | 1987 | 3306248 | D003622:Dapsone / Q000494:pharmacology / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D009166:Mycobacterium leprae / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use*; D012675:Senegal | D004740:English Abstract; D016428:Journal Article | D003622:Dapsone; D012293:Rifampin | [] | false | fre | La résistance de Mycobacterium leprae à la dapsone et à la rifampicine: à propos d'une enquête effectuée dans la région du Cap-Vert (Sénégal). | Med Trop (Mars) | 8710146 | 0025-682X | France | [] | "2024-08-13T08:46:10.523479Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
[Distomatosis of the bile ducts, value of ultrasonics (apropos of a new case)]. | 47(2) | 189-92 | The authors report on a new case of distomatosis localized in the main biliary duct. It has been revealed by a repeated angiocholitis, diagnosed only by endoscopic retrograde cholangiopancreatography. They draw attention on the difficulties to diagnose this clinical form of distomatosis, and underline the interest of ultrasonography in the diagnosis and the selection of therapeutic means. | Medecine tropicale : revue du Corps de sante colonial | [
{
"affiliation": "",
"forename": "B M",
"identifier": "",
"initials": "BM",
"lastname": "Camara"
},
{
"affiliation": "",
"forename": "F G",
"identifier": "",
"initials": "FG",
"lastname": "Cicero"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Sahel"
}
] | 1987 | 3306250 | D000328:Adult; D001649:Bile Duct Diseases / Q000175:diagnosis / Q000469:parasitology*; D005211:Fascioliasis / Q000175:diagnosis*; D005260:Female; D006801:Humans; D014463:Ultrasonography | D002363:Case Reports; D004740:English Abstract; D016428:Journal Article | [] | false | fre | Distomatoses des voies biliaires, intérêt de l'échotomographie. (A propos d'un nouveau cas). | Med Trop (Mars) | 8710146 | 0025-682X | France | [] | "2024-08-13T08:46:10.524250Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Work-related diseases. A new program of the World Health Organization]. | 38(2) | 120-31 | Work-related diseases are multifactorial diseases in which the work environment plays a partial role in causation. They include chronic noncommunicable disease affecting working populations. There is evidence that such diseases as musculoskeletal disorders, hypertension, chronic bronchitis, and several psychosomatic disturbances affecting workers can be attributed to a variety of risk factors, including those in the workplace. Examples of investigations and the occurrence or various work-related diseases are cited from several countries. Occupational health is evolving to deal with multifactorial health problems from combined exposure to occupational and other environmental factors, life-style, and individual susceptibility. More attention should be given to psychosocial factors and ergonomics in the workplace, workers' participation and life-style, multifactorial occupational epidemiology, and new approaches to legislation. A list of research areas is given to cover the present gaps in knowledge. The World Health Organization has started a program of work in this field to identify the magnitude of these diseases in various parts of the world, to stimulate epidemiologic research, and to develop guidelines for control measures. | Medycyna pracy | [
{
"affiliation": "",
"forename": "M A",
"identifier": "",
"initials": "MA",
"lastname": "el Batawi"
}
] | 1987 | 3306261 | D006801:Humans; D009784:Occupational Diseases / Q000517:prevention & control*; D014944:World Health Organization | D004740:English Abstract; D016428:Journal Article; D016454:Review | [] | false | pol | Choroby parazawodowe. Nowy program Swiatowej Organizacji Zdrowia. | Med Pr | 0376642 | 0465-5893 | Poland | [] | "2024-08-13T08:46:10.524968Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Salmonella bacteremia and generalized cryptococcosis, a double indicator of African AIDS]. | 47(2) | 185-8 | A male Rwandese adult with proven A.I.D.S. died from generalized cryptococcosis six months after episodes of recurrent fever with isolation of Salmonella enteritidis from the blood culture. The authors discuss the frequent and precocious appearance of Salmonella septicaemia in patients with A.I.D.S. They propose the inclusion of nontyphoidal Salmonella bacteraemia in the provisional W.H.O. case definition of adult A.I.D.S. in countries with limited diagnostic resources. | Medecine tropicale : revue du Corps de sante colonial | [
{
"affiliation": "",
"forename": "F",
"identifier": "",
"initials": "F",
"lastname": "Rogerie"
},
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Ott"
},
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Wolff"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Vandepitte"
},
{
"affiliation": "",
"forename": "P",
"identifier": "",
"initials": "P",
"lastname": "Lemmens"
}
] | 1987 | 3306249 | D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000382:microbiology; D003453:Cryptococcosis / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012432:Rwanda; D012480:Salmonella Infections / Q000150:complications*; D012477:Salmonella enteritidis; D018805:Sepsis / Q000150:complications* | D002363:Case Reports; D004740:English Abstract; D016428:Journal Article | Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Bacterial And Fungal Diseases; Developing Countries; Diseases; Eastern Africa; Examinations And Diagnoses; French Speaking Africa; Hiv Infections; Infections; Laboratory Examinations And Diagnoses; Physical Examinations And Diagnoses; Rwanda; Viral Diseases | [] | false | fre | Bactériémie à Salmonella et cryptococcose généralisée, double indicateur du S.I.D.A. africain. | 057850; 00187066 | Med Trop (Mars) | 8710146 | 0025-682X | France | [] | "2024-08-13T08:46:10.525854Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||
Extra-intestinal manifestations of salmonella infections. | 66(5) | 349-88 | While salmonellosis is often considered to affect primarily the gastrointestinal tract, infection at other sites may occur, producing characteristic clinical syndromes. We reviewed cases from our institutions and the literature on focal manifestations of salmonella infections. In the past, most extra-intestinal salmonella infections were caused by S. choleraesuis; however, we found S. typhimurium to be the predominant serotype. The mortality rate for patients in our series was considerably lower than the rate described for focal infections in other reviews. This may in part be due to lower proportion of infections due to S. choleraesuis, improved microbiologic and diagnostic techniques, increased use of ampicillin, and improved surgical techniques. Salmonella endocarditis usually occurs in patients with preexisting heart disease. Unlike other salmonella infections, S. choleraesuis is the most frequent serotype. Salmonella endocarditis is often very destructive, with a fatality rate of 70%. Nonvalvular (mural) endocarditis occurs in one-fourth of patients and survival has not been reported. While antibiotic therapy should be tried initially, if response is not prompt the clinician should look for an associated site of infection (intra- or extra-cardiac abscess), which will often require surgery. Salmonella pericarditis often presents with cardiac or pulmonary symptoms, but typical signs of pericardial disease (pulsus paradoxus, friction rub) or characteristic electrocardiographic changes (low voltage, elevated ST segments) are uncommon. Early diagnosis, before infection involves other areas of the heart, is crucial for survival. In addition to antibiotic therapy, pericardiocentesis or pericardiectomy is required. Salmonella may infect the peripheral or visceral arteries, but the abdominal aorta is the most frequent site of vascular infection. Most patients are men over age 50 with preexisting atherosclerosis of the aorta who do not have a previous history of gastroenteritis. About one-fourth of patients have associated lumbar osteomyelitis. No patients have been reported to survive with medical therapy alone. Specific guidelines for surgical removal of infected aneurysms have been proposed and these (in addition to increased use of ampicillin) may be responsible for higher survival rates in recent years. Due to the high incidence of relapses, postoperative blood cultures should be done routinely. Arterial infection should be considered in any elderly patient with salmonella bacteremia especially with prolonged fever or bacteremia after an "adequate course" of antibiotic therapy.(ABSTRACT TRUNCATED AT 400 WORDS) | Medicine | [
{
"affiliation": "",
"forename": "J I",
"identifier": "",
"initials": "JI",
"lastname": "Cohen"
},
{
"affiliation": "",
"forename": "J A",
"identifier": "",
"initials": "JA",
"lastname": "Bartlett"
},
{
"affiliation": "",
"forename": "G R",
"identifier": "",
"initials": "GR",
"lastname": "Corey"
}
] | 1987-09 | 3306260 | D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D000785:Aneurysm, Infected / Q000382:microbiology / Q000503:physiopathology* / Q000601:surgery; D001170:Arthritis, Infectious / Q000382:microbiology* / Q000503:physiopathology; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology; D002675:Child, Preschool; D002701:Chloramphenicol / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology*; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology; D005832:Genital Diseases, Male / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000382:microbiology* / Q000503:physiopathology; D010493:Pericarditis / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology*; D011183:Postoperative Complications; D012480:Salmonella Infections / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology*; D012486:Salmonella typhimurium / Q000302:isolation & purification; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology | D002363:Case Reports; D016428:Journal Article | D002701:Chloramphenicol; D000667:Ampicillin | 10.1097/00005792-198709000-00003 | [] | false | eng | Medicine (Baltimore) | 2985248R | 0025-7974 | United States | [] | "2024-08-13T08:46:10.528322Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
The T cell receptor and autoimmune diseases. | 4(3) | 123-32 | Molecular biology & medicine | [
{
"affiliation": "",
"forename": "M L",
"identifier": "",
"initials": "ML",
"lastname": "Hoover"
},
{
"affiliation": "",
"forename": "J D",
"identifier": "",
"initials": "JD",
"lastname": "Capra"
}
] | 1987-06 | 3306262 | D001327:Autoimmune Diseases / Q000276:immunology*; D002883:Chromosomes, Human, Pair 14; D002897:Chromosomes, Human, Pair 7; D005796:Genes; D006801:Humans; D011110:Polymorphism, Genetic; D011948:Receptors, Antigen, T-Cell / Q000235:genetics* / Q000276:immunology | D016428:Journal Article; D016454:Review | D011948:Receptors, Antigen, T-Cell | [] | false | eng | Mol Biol Med | 8403879 | 0735-1313 | England | [] | "2024-08-13T08:46:10.529276Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
Molecular genetic techniques for mapping the human genome. | 4(3) | 133-43 | Molecular biology & medicine | [
{
"affiliation": "",
"forename": "S M",
"identifier": "",
"initials": "SM",
"lastname": "Weissman"
}
] | 1987-06 | 3306263 | D002874:Chromosome Mapping; D003001:Cloning, Molecular / Q000379:methods; D004247:DNA / Q000235:genetics; D006801:Humans; D008967:Molecular Biology / Q000379:methods* | D016428:Journal Article; D016454:Review | D004247:DNA | [] | false | eng | Mol Biol Med | 8403879 | 0735-1313 | England | [] | "2024-08-13T08:46:10.529897Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
High-level expression in Escherichia coli of a soluble and fully active recombinant interleukin-1 beta. | 4(3) | 169-81 | A complementary DNA sequence encoding monocyte interleukin-1 (IL-1), beta form/pI7, was expressed in Escherichia coli. Recombinant plasmid pDP516 was constructed by cloning and rebuilding the mature IL-1 coding sequence into an E. coli expression vector. Bacteria transformed with pDP516 constitutively produced recombinant IL-1 (r-IL-1) at 15-20% of total E. coli protein. The r-IL-1 was found to be in the soluble fraction of sonicated E. coli Bacterial r-IL-1 (DP516) has been purified to homogeneity by anion exchange and sizing column chromatography, with an apparent molecular weight of 17,500. The identity of the purified r-IL-1 was confirmed by amino acid and DNA sequencing analyses. Purified recombinant IL-1 DP516 exhibits biological activity similar to that of native monocyte IL-1 (3 approximately 4 X 10(7) units/mg). An amino-terminal deletion mutant completely abolishes the biological activity, indicating that the integrity of the IL-1 molecule might be important for its function. | Molecular biology & medicine | [
{
"affiliation": "",
"forename": "J J",
"identifier": "",
"initials": "JJ",
"lastname": "Huang"
},
{
"affiliation": "",
"forename": "R C",
"identifier": "",
"initials": "RC",
"lastname": "Newton"
},
{
"affiliation": "",
"forename": "K",
"identifier": "",
"initials": "K",
"lastname": "Pezzella"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Covington"
},
{
"affiliation": "",
"forename": "T",
"identifier": "",
"initials": "T",
"lastname": "Tamblyn"
},
{
"affiliation": "",
"forename": "S J",
"identifier": "",
"initials": "SJ",
"lastname": "Rutlege"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Gray"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Kelley"
},
{
"affiliation": "",
"forename": "Y",
"identifier": "",
"initials": "Y",
"lastname": "Lin"
}
] | 1987-06 | 3306264 | D000595:Amino Acid Sequence; D001483:Base Sequence; D001681:Biological Assay; D003001:Cloning, Molecular / Q000379:methods; D004926:Escherichia coli / Q000235:genetics; D005786:Gene Expression Regulation; D006801:Humans; D007375:Interleukin-1 / Q000235:genetics* / Q000302:isolation & purification; D010957:Plasmids; D011994:Recombinant Proteins; D012995:Solubility | D016428:Journal Article | D007375:Interleukin-1; D011994:Recombinant Proteins | [] | false | eng | Mol Biol Med | 8403879 | 0735-1313 | England | [] | "2024-08-13T08:46:10.531186Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Sterling D. Garrard Memorial Symposium: Community health care services for adults with mental retardation. November 18, 1986, Auburn, Massachusetts. Proceedings. | 25(4) | 189-238 | Mental retardation | [] | 1987-08 | 3306270 | D000328:Adult; D003153:Community Health Services; D049673:History, 20th Century; D006801:Humans; D008607:Intellectual Disability; D008605:Mental Health Services; D014481:United States | D019215:Biography; D016456:Historical Article; D016428:Journal Article; D019477:Portrait | [] | false | eng | Ment Retard | 18640670R | 0047-6765 | United States | [] | "2024-08-13T08:46:10.531912Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Some thoughts in memory of Sterling Garrard. | 25(4) | 192-4 | Mental retardation | [
{
"affiliation": "",
"forename": "J B",
"identifier": "",
"initials": "JB",
"lastname": "Richmond"
}
] | 1987-08 | 3306271 | D000328:Adult; D002648:Child; D049673:History, 20th Century; D006801:Humans; D008607:Intellectual Disability / Q000266:history; D010372:Pediatrics / Q000266:history; D014481:United States | D019215:Biography; D016456:Historical Article; D016428:Journal Article; D019477:Portrait | [] | false | eng | Ment Retard | 18640670R | 0047-6765 | United States | [] | "2024-08-13T08:46:10.532610Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Recollections about Sterling Garrard. | 25(4) | 195 | Mental retardation | [
{
"affiliation": "",
"forename": "H W",
"identifier": "",
"initials": "HW",
"lastname": "Moser"
}
] | 1987-08 | 3306272 | D000328:Adult; D002648:Child; D049673:History, 20th Century; D006801:Humans; D008607:Intellectual Disability / Q000266:history; D010372:Pediatrics / Q000266:history; D014481:United States | D019215:Biography; D016456:Historical Article; D016428:Journal Article | [] | false | eng | Ment Retard | 18640670R | 0047-6765 | United States | [] | "2024-08-13T08:46:10.533281Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction. | 2(4) | 274-86 | The use of thrombolytic agents to dissolve coronary artery thrombi causing acute transmural myocardial infarctions has been shown to decrease short term mortality, and improve left ventricular function, in patients with acute transmural myocardial infarction. Several thrombolytic agents are currently available which differ mainly in cost, antigenicity, and mechanism of action. Current investigations are being directed at finding safer, more effective thrombolytic agents and at developing optimal therapy following thrombolysis. The complications of thrombolytic therapy are for the most part minor and reversible. Immediate and delayed hypersensitivity to streptokinase is rare. Hypotension and arrhythmias commonly accompany myocardial reperfusion and are usually benign and self-limited. Haemorrhagic complications are the most frequent and serious problems following the use of thrombolytic agents. They can be lessened by the proper selection of patients to avoid those at high risk of bleeding. The avoidance of unnecessary arterial and venous punctures will decrease the incidence of minor but annoying local bleeding. Those agents which are activated at the site of thrombi will hopefully cause fewer bleeding episodes, but early experience with these agents has not been able to demonstrate a lower rate. With careful attention to patient selection and follow-up, thrombolytic agents can be safely and effectively used in the management of patients with acute myocardial infarction. | Medical toxicology and adverse drug experience | [
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Nazari"
},
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Davison"
},
{
"affiliation": "",
"forename": "K",
"identifier": "",
"initials": "K",
"lastname": "Kaplan"
},
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Fintel"
}
] | 1987 | 3306267 | D003326:Coronary Circulation; D003327:Coronary Disease / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000188:drug therapy* / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D010960:Plasminogen Activators / Q000009:adverse effects | D016428:Journal Article; D016454:Review | D005343:Fibrinolytic Agents; D010960:Plasminogen Activators | 10.1007/BF03259869 | [
{
"citation": "Nature. 1952 Nov 29;170(4335):929",
"pmid": "13013265"
},
{
"citation": "Am J Cardiol. 1986 Sep 1;58(6):418-21",
"pmid": "3529908"
},
{
"citation": "Circulation. 1983 Apr;67(4):796-801",
"pmid": "6825235"
},
{
"citation": "Nature. 1981 Apr 9;290(5806):505-8",
"pmid": "7219537"
},
{
"citation": "Am J Cardiol. 1984 Jul 1;54(1):14-9",
"pmid": "6741804"
},
{
"citation": "Clin Cardiol. 1979 Oct;2(5):354-63",
"pmid": "121799"
},
{
"citation": "Ann Intern Med. 1986 Mar;104(3):304-10",
"pmid": "3511819"
},
{
"citation": "Lancet. 1986 Feb 22;1(8478):397-402",
"pmid": "2868337"
},
{
"citation": "Br J Surg. 1969 Aug;56(8):564-7",
"pmid": "5797716"
},
{
"citation": "Semin Thromb Hemost. 1984 Jan;10(1):6-17",
"pmid": "6422555"
},
{
"citation": "N Engl J Med. 1980 Oct 16;303(16):897-902",
"pmid": "7412821"
},
{
"citation": "J Am Coll Cardiol. 1984 Jul;4(1):183-5",
"pmid": "6736447"
},
{
"citation": "Nature. 1947 May 17;159(4046):681",
"pmid": "20342264"
},
{
"citation": "Thromb Haemost. 1986 Apr 30;55(2):259-62",
"pmid": "3520938"
},
{
"citation": "J Allergy Clin Immunol. 1985 Sep;76(3):453-7",
"pmid": "3928729"
},
{
"citation": "Eur Heart J. 1985 Nov;6(11):905-8",
"pmid": "4076201"
},
{
"citation": "N Engl J Med. 1985 Apr 4;312(14):932-6",
"pmid": "4038784"
},
{
"citation": "Am Heart J. 1974 Dec;88(6):705-12",
"pmid": "4608503"
},
{
"citation": "Ann Intern Med. 1979 May;90(5):802-8",
"pmid": "434689"
},
{
"citation": "N Engl J Med. 1986 Jun 5;314(23):1465-71",
"pmid": "2871492"
},
{
"citation": "Am J Cardiol. 1984 May 1;53(9):1209-16",
"pmid": "6711421"
},
{
"citation": "N Engl J Med. 1982 May 27;306(21):1268-76",
"pmid": "7040966"
},
{
"citation": "Proc Soc Exp Biol Med. 1953 Feb;82(2):291-5",
"pmid": "13037876"
},
{
"citation": "Am Heart J. 1986 Sep;112(3):468-71",
"pmid": "3751860"
},
{
"citation": "J Biol Chem. 1986 Jan 25;261(3):1267-73",
"pmid": "3080422"
},
{
"citation": "Am J Cardiol. 1984 Aug 1;54(3):256-60",
"pmid": "6465000"
},
{
"citation": "Am J Cardiol. 1985 Apr 1;55(8):878-82",
"pmid": "3984876"
},
{
"citation": "N Engl J Med. 1979 Dec 6;301(23):1266-70",
"pmid": "503130"
},
{
"citation": "Eur Heart J. 1985 Jul;6(7):556-85",
"pmid": "3899654"
},
{
"citation": "Circulation. 1983 Aug;68(2 Pt 2):I25-36",
"pmid": "6861325"
},
{
"citation": "JAMA. 1970 Dec 21;214(12):2163-72",
"pmid": "5536580"
},
{
"citation": "Circulation. 1986 Nov;74(5):1066-70",
"pmid": "2429783"
},
{
"citation": "Eur J Biochem. 1976 Oct 1;69(1):209-16",
"pmid": "136345"
},
{
"citation": "JAMA. 1983 Apr 15;249(15):2020-1",
"pmid": "6834592"
},
{
"citation": "Circulation. 1983 Mar;67(3):536-48",
"pmid": "6821895"
},
{
"citation": "Ann Intern Med. 1980 Jul;93(1):141-4",
"pmid": "7396293"
},
{
"citation": "J Lab Clin Med. 1965 May;65:713-31",
"pmid": "14281368"
},
{
"citation": "Thromb Haemost. 1986 Aug 20;56(1):1-5",
"pmid": "3095944"
},
{
"citation": "Biochem J. 1976 Dec 1;159(3):545-53",
"pmid": "137718"
},
{
"citation": "Am J Cardiol. 1987 Feb 1;59(4):241-4",
"pmid": "3812272"
},
{
"citation": "JAMA. 1974 Sep 16;229(12):1606-13",
"pmid": "4408392"
},
{
"citation": "Circulation. 1984 Oct;70(4):606-18",
"pmid": "6383654"
},
{
"citation": "Lancet. 1946 Oct 19;2(6425):562-5",
"pmid": "21001709"
},
{
"citation": "Ann Intern Med. 1973 Nov;79(5):712-9",
"pmid": "4584570"
},
{
"citation": "Int J Cardiol. 1986 Apr;11(1):53-61",
"pmid": "3514485"
},
{
"citation": "Drugs. 1987 Jul;34(1):25-49",
"pmid": "3308411"
},
{
"citation": "Biochim Biophys Acta. 1977 Feb 28;496(2):384-400",
"pmid": "836903"
},
{
"citation": "Circulation. 1981 Mar;63(3):489-97",
"pmid": "7460232"
},
{
"citation": "Thromb Haemost. 1980 Jun 18;43(2):77-89",
"pmid": "6450468"
},
{
"citation": "N Engl J Med. 1983 Dec 15;309(24):1477-82",
"pmid": "6358886"
},
{
"citation": "Thromb Diath Haemorrh. 1975 Nov 15;34(2):403-8",
"pmid": "1105875"
},
{
"citation": "Ann Intern Med. 1986 Mar;104(3):345-8",
"pmid": "3080936"
},
{
"citation": "J Biol Chem. 1986 Jan 25;261(3):1253-8",
"pmid": "2935528"
},
{
"citation": "Circulation. 1983 Nov;68(5):1051-61",
"pmid": "6352081"
},
{
"citation": "Biochemistry. 1986 Jul 15;25(14):4041-5",
"pmid": "3527262"
},
{
"citation": "N Engl J Med. 1982 Dec 23;307(26):1627-30",
"pmid": "7144849"
},
{
"citation": "Am Heart J. 1986 Nov;112(5):928-32",
"pmid": "3776819"
},
{
"citation": "Am J Cardiol. 1984 Feb 1;53(4):626-7",
"pmid": "6364763"
},
{
"citation": "Trans Assoc Am Physicians. 1958;71:287-96",
"pmid": "13603526"
},
{
"citation": "Clin Exp Immunol. 1985 Nov;62(2):421-6",
"pmid": "4085148"
},
{
"citation": "Arch Intern Med. 1986 Feb;146(2):305-7",
"pmid": "3947191"
},
{
"citation": "Proc Soc Exp Biol Med. 1971 Oct;138(1):277-80",
"pmid": "5125527"
},
{
"citation": "Adv Neurol. 1978;19:249-60",
"pmid": "369322"
},
{
"citation": "Am J Cardiol. 1983 Aug;52(3):221-4",
"pmid": "6869265"
},
{
"citation": "Ann Intern Med. 1984 Apr;100(4):617",
"pmid": "6703562"
},
{
"citation": "Circulation. 1983 Aug;68(2 Pt 2):I16-24",
"pmid": "6305533"
},
{
"citation": "Circulation. 1985 Nov;72(5):1053-8",
"pmid": "4042294"
},
{
"citation": "J Biol Chem. 1976 Oct 10;251(19):5956-65",
"pmid": "134998"
},
{
"citation": "Am Heart J. 1983 Jan;105(1):26-32",
"pmid": "6849238"
},
{
"citation": "Lancet. 1985 Apr 13;1(8433):842-7",
"pmid": "2858711"
},
{
"citation": "JAMA. 1984 Sep 14;252(10):1314-7",
"pmid": "6433051"
},
{
"citation": "Circulation. 1984 Apr;69(4):756-60",
"pmid": "6607784"
}
] | false | eng | Med Toxicol Adverse Drug Exp | 8709214 | 0113-5244 | New Zealand | [] | "2024-08-13T08:46:10.536113Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Clinical features and management of poisoning due to antimalarial drugs. | 2(4) | 242-73 | The toxicities of antimalarial drugs vary because of the differences in the chemical structures of these compounds. Quinine, the oldest antimalarial, has been used for 300 years. Of the 200 to 300 compounds synthesised since the first synthetic antimalarial, primaquine in 1926, 15 to 20 are currently used for malaria treatment, most of which are quinoline derivatives. Quinoline derivatives, particularly quinine and chloroquine, are highly toxic in overdose. The toxic effects are related to their quinidine-like actions on the heart and include circulatory arrest, cardiogenic shock, conduction disturbances and ventricular arrhythmias. Additional clinical features are obnubilation, coma, convulsions, respiratory depression. Blindness is a frequent complication in quinine overdose. Hypokalaemia is consistently present, although apparently self-correcting, in severe chloroquine poisoning and is a good index of severity. Recent toxicokinetic studies of quinine and chloroquine showed good correlations between dose ingested, serum concentrations and clinical features, and confirmed the inefficacy of haemodialysis, haemoperfusion and peritoneal dialysis for enhancing drug removal. The other quinoline derivatives appear to be less toxic. Amodiaquine may induce side effects such as gastrointestinal symptoms, agranulocytosis and hepatitis. The main feature of primaquine overdose is methaemoglobinaemia. No cases of mefloquine and piperaquine overdose have been reported. Overdose with quinacrine, an acridine derivative, may result in nausea, vomiting, confusion, convulsion and acute psychosis. The dehydrofolate reductase inhibitors used in malaria treatment are sulfadoxine, dapsone, proguanil (chloroguanide), trimethoprim and pyrimethamine. Most of these drugs are given in combination. Proguanil is one of the safest antimalarials. Convulsion, coma and blindness have been reported in pyrimethamine overdose. Sulfadoxine can induce Lyell and Stevens-Johnson syndromes. The main feature of dapsone poisoning is severe methaemoglobinaemia which is related to dapsone and to its metabolites. Recent toxicokinetic studies confirmed the efficacy of oral activated charcoal, haemodialysis and haemoperfusion in enhancing removal of dapsone and its metabolites. No overdose has been reported with artemesinine, a new antimalarial tested in the People's Republic of China. The general management of antimalarial overdose include gastric lavage and symptomatic treatment.(ABSTRACT TRUNCATED AT 400 WORDS) | Medical toxicology and adverse drug experience | [
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Jaeger"
},
{
"affiliation": "",
"forename": "P",
"identifier": "",
"initials": "P",
"lastname": "Sauder"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Kopferschmitt"
},
{
"affiliation": "",
"forename": "F",
"identifier": "",
"initials": "F",
"lastname": "Flesch"
}
] | 1987 | 3306266 | D000962:Antimalarials / Q000506:poisoning*; D006801:Humans | D016428:Journal Article; D016454:Review | D000962:Antimalarials | 10.1007/BF03259868 | [
{
"citation": "Drug Metab Dispos. 1975 May-Jun;3(3):198-210",
"pmid": "238819"
},
{
"citation": "Circ Res. 1959 Jan;7(1):86-92",
"pmid": "13619046"
},
{
"citation": "Br J Clin Pharmacol. 1980 Oct;10(4):399-404",
"pmid": "6934796"
},
{
"citation": "Clin Pharmacol Ther. 1975 Dec;18(6):670-9",
"pmid": "1204275"
},
{
"citation": "Acta Med Scand. 1983;214(3):215-20",
"pmid": "6660028"
},
{
"citation": "East Afr Med J. 1966 Oct;43(10):405-8",
"pmid": "5341684"
},
{
"citation": "Clin Nephrol. 1974 Jan-Feb;2(1):44-6",
"pmid": "4823494"
},
{
"citation": "Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225-38",
"pmid": "5554939"
},
{
"citation": "Bull Soc Pathol Exot Filiales. 1979 Jan-Feb;72(1):86-92",
"pmid": "498390"
},
{
"citation": "Br J Clin Pharmacol. 1983 Apr;15(4):502-3",
"pmid": "6849790"
},
{
"citation": "Klin Wochenschr. 1965 Dec 15;43(24):1332-4",
"pmid": "5896035"
},
{
"citation": "Am Heart J. 1963 Jan;65:102-9",
"pmid": "13949513"
},
{
"citation": "Br Med J. 1976 Jul 24;2(6029):214-5",
"pmid": "974497"
},
{
"citation": "Clin Nephrol. 1982 Aug;18(2):106-8",
"pmid": "7140018"
},
{
"citation": "Lancet. 1950 May 13;1(6611):905-6",
"pmid": "15416073"
},
{
"citation": "Chemotherapy. 1976;22(6):390-409",
"pmid": "954483"
},
{
"citation": "Clin Pharmacol Ther. 1979 Sep;26(3):372-9",
"pmid": "466930"
},
{
"citation": "Nouv Presse Med. 1981 Oct 3;10(35):2883-7",
"pmid": "7290940"
},
{
"citation": "Br J Haematol. 1980 Jul;45(3):361-70",
"pmid": "7426431"
},
{
"citation": "Br Med J (Clin Res Ed). 1985 Jul 6;291(6487):31-3",
"pmid": "3926054"
},
{
"citation": "Southeast Asian J Trop Med Public Health. 1982 Dec;13(4):556-62",
"pmid": "6763356"
},
{
"citation": "Lancet. 1985 Mar 30;1(8431):752-3",
"pmid": "2858017"
},
{
"citation": "Adverse Drug React Acute Poisoning Rev. 1986 Winter;5(4):215-33",
"pmid": "3548270"
},
{
"citation": "Clin Nephrol. 1981 Nov;16(5):264-8",
"pmid": "7307355"
},
{
"citation": "Br J Clin Pharmacol. 1984 Apr;17(4):441-6",
"pmid": "6721990"
},
{
"citation": "Arch Intern Med (Chic). 1947 Dec;80(6):763-70",
"pmid": "18897478"
},
{
"citation": "J Tradit Chin Med. 1982 Mar;2(1):31-8",
"pmid": "6765846"
},
{
"citation": "Br J Clin Pharmacol. 1982 Oct;14(4):483-7",
"pmid": "6753885"
},
{
"citation": "Br J Clin Pharmacol. 1983 Dec;16(6):701-5",
"pmid": "6661356"
},
{
"citation": "Br J Dermatol. 1979 Apr;100(4):427-32",
"pmid": "454569"
},
{
"citation": "Z Rechtsmed. 1984;92(1):27-33",
"pmid": "6720097"
},
{
"citation": "Arch Ophthalmol. 1973 Oct;90(4):307-9",
"pmid": "4746646"
},
{
"citation": "Ann Fr Anesth Reanim. 1982;1(3):321-3",
"pmid": "7165147"
},
{
"citation": "Postgrad Med J. 1983 Jun;59(692):365-7",
"pmid": "6634542"
},
{
"citation": "Aust N Z J Med. 1983 Oct;13(5):509-12",
"pmid": "6228217"
},
{
"citation": "J Clin Psychiatry. 1981 Apr;42(4):162-4",
"pmid": "7204361"
},
{
"citation": "Br J Clin Pharmacol. 1983 Apr;15(4):471-9",
"pmid": "6849784"
},
{
"citation": "Br Med J. 1955 Jul 9;2(4931):94-6",
"pmid": "14378652"
},
{
"citation": "N Engl J Med. 1982 Dec 9;307(24):1529-30",
"pmid": "7144829"
},
{
"citation": "Br Med J. 1963 Sep 14;2(5358):662-4",
"pmid": "14044869"
},
{
"citation": "Int J Clin Pharmacol Biopharm. 1978 Sep;16(9):395-401",
"pmid": "359493"
},
{
"citation": "Am J Trop Med Hyg. 1972 Mar;21(2):138-43",
"pmid": "4551432"
},
{
"citation": "J Toxicol Clin Exp. 1986 Sep-Oct;6(5):307-12",
"pmid": "3795134"
},
{
"citation": "Br Med J. 1973 Oct 20;4(5885):147-8",
"pmid": "4543103"
},
{
"citation": "Lancet. 1986 Feb 22;1(8478):411-4",
"pmid": "2868340"
},
{
"citation": "Arch Ophthalmol. 1982 Aug;100(8):1300-4",
"pmid": "7103815"
},
{
"citation": "J Lab Clin Med. 1973 Feb;81(2):267-72",
"pmid": "4683425"
},
{
"citation": "J Toxicol Clin Toxicol. 1984-1985;22(6):537-48",
"pmid": "6535846"
},
{
"citation": "Chemotherapy. 1983;29(3):184-7",
"pmid": "6603336"
},
{
"citation": "Eur J Toxicol Hyg Environ. 1973 Mar-Apr;6(2):85-93",
"pmid": "4783735"
},
{
"citation": "Clin Toxicol. 1978;13(3):361-9",
"pmid": "743865"
},
{
"citation": "Drug Metab Dispos. 1978 May-Jun;6(3):329-37",
"pmid": "26555"
},
{
"citation": "Nouv Presse Med. 1981 Sep 26;10(34):2827-8",
"pmid": "7312594"
},
{
"citation": "Chemotherapy. 1982;28(1):70-84",
"pmid": "6976886"
},
{
"citation": "Bull World Health Organ. 1982;60(6):929-32",
"pmid": "6761007"
},
{
"citation": "Pol Arch Med Wewn. 1972 Feb;49(2):181-6",
"pmid": "4670216"
},
{
"citation": "Pediatrics. 1961 Jan;27:95-102",
"pmid": "13690445"
},
{
"citation": "Hum Toxicol. 1984 Oct;3(5):399-402",
"pmid": "6149188"
},
{
"citation": "J Trop Med Hyg. 1963 Nov;66:292-5",
"pmid": "14075517"
},
{
"citation": "Med J Aust. 1977 Feb 26;1(9):298-9",
"pmid": "859490"
},
{
"citation": "J Toxicol Clin Toxicol. 1983 May;20(3):271-9",
"pmid": "6620441"
},
{
"citation": "Am J Trop Med Hyg. 1976 Nov;25(6):769-74",
"pmid": "795309"
},
{
"citation": "J Pharmacol Exp Ther. 1973 Oct;187(1):138-51",
"pmid": "4583459"
},
{
"citation": "Arch Dis Child. 1980 Jun;55(6):478",
"pmid": "7436489"
},
{
"citation": "J Pharm Pharmacol. 1970 Sep;22(9):700-3",
"pmid": "4394763"
},
{
"citation": "Am J Med Sci. 1959 Feb;237(2):165-76 passim",
"pmid": "13626959"
},
{
"citation": "Anaesthesia. 1979 Nov-Dec;34(10):1041-2",
"pmid": "539641"
},
{
"citation": "J Toxicol Clin Exp. 1986 Sep-Oct;6(5):333-9",
"pmid": "3795139"
},
{
"citation": "Chin Med J (Engl). 1982 Apr;95(4):281-6",
"pmid": "6813038"
},
{
"citation": "Ann Trop Med Parasitol. 1946 Dec;40(3-4):493-506",
"pmid": "20289245"
},
{
"citation": "Cardiovasc Res. 1979 Nov;13(11):630-4",
"pmid": "519665"
},
{
"citation": "J Toxicol Clin Toxicol. 1982 Mar;19(1):45-50",
"pmid": "7154140"
},
{
"citation": "Clin Pharmacol Ther. 1979 Mar;25(3):345-50",
"pmid": "310749"
},
{
"citation": "Lancet. 1985 Feb 16;1(8425):384-5",
"pmid": "2857431"
},
{
"citation": "Eur J Toxicol. 1972 May-Jun;5(3):189-202",
"pmid": "4648045"
},
{
"citation": "Clin Pharmacol Ther. 1976 Apr;19(4):459-67",
"pmid": "773582"
},
{
"citation": "J Clin Invest. 1956 Feb;35(2):223-35",
"pmid": "13286341"
},
{
"citation": "Toxicol Appl Pharmacol. 1977 Jun;40(3):437-48",
"pmid": "882980"
},
{
"citation": "Clin Pharmacokinet. 1985 May-Jun;10(3):187-215",
"pmid": "3893840"
},
{
"citation": "Int J Clin Pharmacol Ther Toxicol. 1985 May;23(5):253-7",
"pmid": "4008114"
},
{
"citation": "Br J Clin Pharmacol. 1983 Oct;16(4):399-403",
"pmid": "6626434"
},
{
"citation": "J Trop Med Hyg. 1976 Dec;79(12):264-9",
"pmid": "1011322"
},
{
"citation": "Dakar Med. 1983;28(4):593-602",
"pmid": "6678730"
},
{
"citation": "Am J Cardiol. 1959 Mar;3(3):294-9",
"pmid": "13626863"
},
{
"citation": "AMA Arch Intern Med. 1957 Oct;100(4):565-81",
"pmid": "13457482"
},
{
"citation": "Med Clin North Am. 1974 Sep;58(5):1093-102",
"pmid": "4418783"
},
{
"citation": "Med J Aust. 1970 Jun 6;1(23):1158-9",
"pmid": "5431754"
},
{
"citation": "Dtsch Med Wochenschr. 1970 Mar 6;95(10):517-21",
"pmid": "5413764"
},
{
"citation": "J Tradit Chin Med. 1982 Mar;2(1):25-30",
"pmid": "6765844"
},
{
"citation": "Am J Ophthalmol. 1980 Sep;90(3):403-10",
"pmid": "7425057"
},
{
"citation": "Vet Hum Toxicol. 1979;21 Suppl:68-9",
"pmid": "505991"
},
{
"citation": "Am Heart J. 1970 Jun;79(6):831-42",
"pmid": "5419357"
},
{
"citation": "N Z Med J. 1981 Sep 23;94(692):215-6",
"pmid": "6946315"
},
{
"citation": "Chemotherapy. 1969;14(4):195-226",
"pmid": "4981614"
},
{
"citation": "South Med J. 1974 Sep;67(9):1031-5",
"pmid": "4851012"
},
{
"citation": "J Trop Med Hyg. 1979 Feb;82(2):36-7",
"pmid": "458905"
},
{
"citation": "Q J Med. 1985 Feb;54(214):125-31",
"pmid": "3983356"
},
{
"citation": "J Toxicol Clin Toxicol. 1982 Dec;19(10):1061-6",
"pmid": "7184998"
},
{
"citation": "Med Trop (Mars). 1958 Mar-Apr;18(2):305-11",
"pmid": "13551377"
},
{
"citation": "Am J Med. 1982 Oct;73(4):564-72",
"pmid": "6751085"
},
{
"citation": "J Toxicol Clin Toxicol. 1985-1986;23(7-8):571-8",
"pmid": "3831380"
},
{
"citation": "Pediatrics. 1975 Apr;55(4):536-8",
"pmid": "1128962"
},
{
"citation": "J Lab Clin Med. 1976 Jul;88(1):87-90",
"pmid": "932536"
},
{
"citation": "Arch Intern Med. 1960 Jan;105:13-22",
"pmid": "13795835"
},
{
"citation": "Exp Parasitol. 1963 Apr;13:178-85",
"pmid": "13993147"
},
{
"citation": "J Pharmacol Exp Ther. 1967 Nov;158(2):323-31",
"pmid": "6065153"
},
{
"citation": "Br J Clin Pract. 1969 Aug;23(8):331-4",
"pmid": "5801679"
},
{
"citation": "Br Med J (Clin Res Ed). 1986 Mar 15;292(6522):721-3",
"pmid": "3082410"
},
{
"citation": "Eur J Clin Pharmacol. 1984;26(4):521-30",
"pmid": "6610555"
},
{
"citation": "J Toxicol Clin Toxicol. 1982 Dec;19(10):1067-71",
"pmid": "7184999"
},
{
"citation": "Therapie. 1966 Mar-Apr;21(2):387-95",
"pmid": "5935648"
},
{
"citation": "Clin Toxicol. 1979;14(1):79-85",
"pmid": "436385"
},
{
"citation": "Therapie. 1985 Sep-Oct;40(5):357-9",
"pmid": "4095694"
},
{
"citation": "J Pharmacol Exp Ther. 1966 Nov;154(2):250-4",
"pmid": "5922987"
},
{
"citation": "Bull Soc Pathol Exot Filiales. 1985;78(5 Pt 2):959-64",
"pmid": "3915449"
},
{
"citation": "Ann Intern Med. 1986 Jun;104(6):801-3",
"pmid": "2871789"
},
{
"citation": "Hum Toxicol. 1983 Jul;2(3):507-10",
"pmid": "6885095"
},
{
"citation": "Biochem Pharmacol. 1972 May 1;21(9):1265-74",
"pmid": "5038672"
},
{
"citation": "Hum Toxicol. 1986 Jul;5(4):221-7",
"pmid": "3733111"
},
{
"citation": "Ann Dermatol Syphiligr (Paris). 1968;95(5):481-90",
"pmid": "4238450"
},
{
"citation": "Med J Aust. 1978 Oct 21;2(9):407-10",
"pmid": "732727"
},
{
"citation": "Toxicol Appl Pharmacol. 1972 Apr;21(4):464-81",
"pmid": "5047047"
},
{
"citation": "Chest. 1980 Oct;78(4):654-6",
"pmid": "7418494"
}
] | false | eng | Med Toxicol Adverse Drug Exp | 8709214 | 0113-5244 | New Zealand | [] | "2024-08-13T08:46:10.540313Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Systemic reactions to ophthalmic drug preparations. | 2(4) | 287-93 | Adverse systemic reactions associated with the use of topical ophthalmic timolol, chloramphenicol, phenylephrine and cyclopentolate are surveyed, with special emphasis on precautions and contraindications for these ophthalmic drug preparations. Systemic reactions secondary to timolol, a beta-adrenergic antagonist indicate that it should be used with caution in patients with asthma or a history of asthma, chronic obstructive pulmonary disease or cardiovascular disease and in those patients receiving systemic administration of beta-blockers or verapamil. Because significant blood dyscrasias or aplastic anaemia have been reported following topical ophthalmic chloramphenicol, the only absolute indication in ocular conditions is an organism that is resistant to all other antibiotics. Both 2.5% and 10% phenylephrine have been associated with cardiovascular effects and should be used with caution in selected patients on monoamine oxidase inhibitors, tricyclic antidepressants or atropine or in those with hypertension, advanced arteriosclerotic changes, aneurysms, orthostatic hypotension, long-standing insulin-dependent diabetes and in children with low bodyweights. Central nervous system toxicity secondary to cyclopentolate is dose-related and can be avoided by use of minimal concentrations and avoidance of unnecessary repetition of administration. Occlusion of the nasolacrimal passage with finger pressure immediately after instillation of any eyedrop also decreases the amount of drug that is absorbed systemically. | Medical toxicology and adverse drug experience | [
{
"affiliation": "",
"forename": "F T",
"identifier": "",
"initials": "FT",
"lastname": "Fraunfelder"
},
{
"affiliation": "",
"forename": "S M",
"identifier": "",
"initials": "SM",
"lastname": "Meyer"
}
] | 1987 | 3306268 | D002701:Chloramphenicol / Q000009:adverse effects; D003519:Cyclopentolate / Q000009:adverse effects; D006801:Humans; D009883:Ophthalmic Solutions / Q000009:adverse effects*; D010656:Phenylephrine / Q000009:adverse effects; D013999:Timolol / Q000009:adverse effects | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't; D013487:Research Support, U.S. Gov't, P.H.S.; D016454:Review | D009883:Ophthalmic Solutions; D010656:Phenylephrine; D002701:Chloramphenicol; D013999:Timolol; D003519:Cyclopentolate | 10.1007/BF03259870 | [
{
"citation": "Am J Ophthalmol. 1985 Feb 15;99(2):180-4",
"pmid": "3970123"
},
{
"citation": "Arch Ophthalmol. 1984 Apr;102(4):551-3",
"pmid": "6704011"
},
{
"citation": "Trans Ophthalmol Soc U K. 1974 Jul;94(2):487-95",
"pmid": "4143267"
},
{
"citation": "Ann Ophthalmol. 1985 Jan;17(1):64-5",
"pmid": "3977221"
},
{
"citation": "J Pediatr. 1973 Mar;82(3):501-5",
"pmid": "4698940"
},
{
"citation": "Am J Ophthalmol. 1982 Mar;93(3):356-60",
"pmid": "7072798"
},
{
"citation": "Am J Ophthalmol. 1963 Jun;55:1243-5",
"pmid": "13968361"
},
{
"citation": "J Pediatr Ophthalmol Strabismus. 1981 Nov-Dec;18(6):42-4",
"pmid": "7334446"
},
{
"citation": "Can Med Assoc J. 1979 May 19;120(10):1261-2",
"pmid": "221086"
},
{
"citation": "N Engl J Med. 1984 Nov 29;311(22):1441",
"pmid": "6493304"
},
{
"citation": "Pediatrics. 1981 Aug;68(2):231-4",
"pmid": "7267230"
},
{
"citation": "Ann Ophthalmol. 1981 Mar;13(3):311-3",
"pmid": "7258938"
},
{
"citation": "Ophthalmology. 1984 Nov;91(11):1361-3",
"pmid": "6514303"
},
{
"citation": "JAMA. 1979 Oct 12;242(15):1611-2",
"pmid": "39182"
},
{
"citation": "Arch Intern Med. 1981 Sep;141(10):1384-5",
"pmid": "6115627"
},
{
"citation": "Ophthalmologica. 1980;181(3-4):228-30",
"pmid": "7231890"
},
{
"citation": "Am J Ophthalmol. 1979 Jun;87(6):819-22",
"pmid": "453312"
},
{
"citation": "JAMA. 1965 Jan 11;191:136-7",
"pmid": "14233236"
},
{
"citation": "Clin Pharmacokinet. 1980 Jan-Feb;5(1):95-100",
"pmid": "7363532"
},
{
"citation": "Ann Neurol. 1985 Feb;17(2):211-2",
"pmid": "3977305"
},
{
"citation": "Arch Ophthalmol. 1967 Oct;78(4):445-7",
"pmid": "6046837"
},
{
"citation": "Am J Ophthalmol. 1983 Apr;95(4):562-3",
"pmid": "6837708"
},
{
"citation": "Lancet. 1977 Oct 15;2(8042):827",
"pmid": "71637"
},
{
"citation": "JAMA. 1980 Dec 19;244(24):2730",
"pmid": "7441859"
},
{
"citation": "Pediatrics. 1973 Jun;51(6):1032-6",
"pmid": "4575724"
},
{
"citation": "N Engl J Med. 1979 Mar 8;300(10):566",
"pmid": "763265"
},
{
"citation": "Arch Intern Med. 1983 Aug;143(8):1627",
"pmid": "6870450"
},
{
"citation": "Am J Ophthalmol. 1985 Mar 15;99(3):362-3",
"pmid": "3976814"
},
{
"citation": "Anesthesiology. 1972 Feb;36(2):187-9",
"pmid": "5059112"
},
{
"citation": "J Pediatr. 1971 Jul;79(1):127-9",
"pmid": "5091252"
},
{
"citation": "Br Med J (Clin Res Ed). 1987 Jan 17;294(6565):155-6",
"pmid": "3109547"
},
{
"citation": "AMA Arch Ophthalmol. 1956 Aug;56(2):176-9",
"pmid": "13354057"
},
{
"citation": "JAMA. 1980 Nov 21;244(20):2263",
"pmid": "7001053"
},
{
"citation": "Am J Ophthalmol. 1986 Nov 15;102(5):606-11",
"pmid": "3777080"
},
{
"citation": "Am J Ophthalmol. 1964 Dec;58:1060-1",
"pmid": "14233710"
},
{
"citation": "Lancet. 1975 Aug 16;2(7929):326-7",
"pmid": "50539"
},
{
"citation": "Klin Monbl Augenheilkd. 1979 Jul;175(1):100-2",
"pmid": "491456"
},
{
"citation": "Ophthalmology. 1985 May;92(5):698-700",
"pmid": "4011145"
},
{
"citation": "Ann Ophthalmol. 1976 Jul;8(7):803-6",
"pmid": "962257"
},
{
"citation": "Arch Ophthalmol. 1981 Apr;99(4):696",
"pmid": "7224942"
},
{
"citation": "J Ocul Pharmacol. 1985 Spring;1(1):79-83",
"pmid": "3880069"
},
{
"citation": "Ophthalmologica. 1981;182(3):153-6",
"pmid": "7267004"
},
{
"citation": "Am J Ophthalmol. 1984 Aug 15;98(2):244-5",
"pmid": "6476051"
},
{
"citation": "Anesth Analg. 1973 Mar;52(2):161-5",
"pmid": "4735272"
},
{
"citation": "JAMA. 1982 Mar 19;247(11):1567",
"pmid": "7062457"
},
{
"citation": "Am J Ophthalmol. 1984 Nov;98(5):623-4",
"pmid": "6149687"
},
{
"citation": "Br J Clin Pharmacol. 1985 Mar;19(3):329-33",
"pmid": "2859048"
},
{
"citation": "JAMA. 1980 Aug 22-29;244(8):768-9",
"pmid": "7392179"
},
{
"citation": "Arch Ophthalmol. 1972 Jun;87(6):634-5",
"pmid": "4624379"
},
{
"citation": "Arch Intern Med. 1986 Jun;146(6):1220-1",
"pmid": "3718111"
},
{
"citation": "Am J Ophthalmol. 1978 Jun;85(6):862-8",
"pmid": "677215"
},
{
"citation": "Can J Ophthalmol. 1978 Oct;13(4):290-3",
"pmid": "743613"
},
{
"citation": "Arch Intern Med. 1980 Apr;140(4):576-7",
"pmid": "7362398"
},
{
"citation": "Am J Ophthalmol. 1973 Jul;76(1):156-7",
"pmid": "4717333"
},
{
"citation": "Am J Dis Child. 1985 Apr;139(4):367-8",
"pmid": "3838413"
},
{
"citation": "Ophthalmology. 1980 May;87(5):447-50",
"pmid": "7402590"
},
{
"citation": "Am J Ophthalmol. 1978 Apr;85(4):447-53",
"pmid": "655224"
},
{
"citation": "Indian J Ophthalmol. 1975 Apr;23(1):16-7",
"pmid": "1158416"
},
{
"citation": "JAMA. 1985 Jun 7;253(21):3092-3",
"pmid": "3999290"
},
{
"citation": "Am J Ophthalmol. 1966 Jan;61(1):95-8",
"pmid": "5904383"
},
{
"citation": "Am J Ophthalmol. 1982 Mar;93(3):369-70",
"pmid": "7072801"
},
{
"citation": "Arch Ophthalmol. 1962 Apr;67:406-8",
"pmid": "13912993"
}
] | false | eng | Med Toxicol Adverse Drug Exp | 8709214 | 0113-5244 | New Zealand | [
{
"agency": "PHS HHS",
"country": "United States",
"grant_acronym": "",
"grant_id": "223-85-1600"
}
] | "2024-08-13T08:46:10.544697Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Medicaid after 20 years: promise, problems, potential. | 25(4) | 211-4 | Mental retardation | [
{
"affiliation": "",
"forename": "R J",
"identifier": "",
"initials": "RJ",
"lastname": "Master"
}
] | 1987-08 | 3306274 | D000328:Adult; D002648:Child; D003365:Costs and Cost Analysis; D004495:Education of Intellectually Disabled / Q000191:economics*; D006801:Humans; D008404:Massachusetts; D008484:Medicaid / Q000191:economics*; D012051:Reimbursement Mechanisms / Q000191:economics | D016428:Journal Article | [] | false | eng | Ment Retard | 18640670R | 0047-6765 | United States | [] | "2024-08-13T08:46:10.545760Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
The thinking of Sterling Garrard. | 25(4) | 196-7 | Mental retardation | [
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Yankauer"
}
] | 1987-08 | 3306273 | D000328:Adult; D002648:Child; D049673:History, 20th Century; D006801:Humans; D008607:Intellectual Disability / Q000266:history; D010372:Pediatrics / Q000266:history; D014481:United States | D019215:Biography; D016456:Historical Article; D016428:Journal Article | [] | false | eng | Ment Retard | 18640670R | 0047-6765 | United States | [] | "2024-08-13T08:46:10.546416Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Bibliography of principal references on health and medical concerns for adults with mental retardation. | 25(4) | 239-42 | Mental retardation | [
{
"affiliation": "",
"forename": "J M",
"identifier": "",
"initials": "JM",
"lastname": "Gleason"
},
{
"affiliation": "",
"forename": "C",
"identifier": "",
"initials": "C",
"lastname": "Browne"
},
{
"affiliation": "",
"forename": "E R",
"identifier": "",
"initials": "ER",
"lastname": "Gilmore"
}
] | 1987-08 | 3306275 | D000328:Adult; D001634:Bibliographies as Topic; D003191:Comprehensive Health Care; D006801:Humans; D008607:Intellectual Disability / Q000628:therapy* | D016417:Bibliography; D016428:Journal Article | [] | false | eng | Ment Retard | 18640670R | 0047-6765 | United States | [] | "2024-08-13T08:46:10.547575Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Rare and serious adverse reactions. | 2(4) | 235-41 | Medical toxicology and adverse drug experience | [
{
"affiliation": "",
"forename": "G R",
"identifier": "",
"initials": "GR",
"lastname": "Venning"
}
] | 1987 | 3306265 | D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D006113:United Kingdom | D016428:Journal Article; D016454:Review | 10.1007/BF03259867 | [
{
"citation": "N Engl J Med. 1972 Dec 21;287(25):1259-64",
"pmid": "4636892"
},
{
"citation": "Lancet. 1986 Aug 23;2(8504):440-4",
"pmid": "2874423"
},
{
"citation": "Br Med J (Clin Res Ed). 1981 Apr 11;282(6271):1216-7",
"pmid": "6788140"
},
{
"citation": "Br Med J. 1975 May 3;2(5965):241-5",
"pmid": "1169093"
},
{
"citation": "Med Toxicol. 1986 Jul-Aug;1(4):237-46",
"pmid": "3537618"
},
{
"citation": "Cancer. 1970 Apr;25(4):745-57",
"pmid": "5443099"
},
{
"citation": "Hum Toxicol. 1982 Oct;1(4):379-86",
"pmid": "7173922"
},
{
"citation": "Br Med J (Clin Res Ed). 1983 Jan 22;286(6361):289-92",
"pmid": "6218859"
},
{
"citation": "JAMA. 1974 May 6;228(6):713-7",
"pmid": "4406257"
},
{
"citation": "Br Med J. 1968 Apr 27;2(5599):193-9",
"pmid": "5653024"
},
{
"citation": "Br Med J. 1967 May 6;2(5548):355-9",
"pmid": "6023133"
},
{
"citation": "Br Med J (Clin Res Ed). 1983 Jan 29;286(6362):365-8",
"pmid": "6402104"
},
{
"citation": "Br Med J. 1969 Apr 12;2(5649):69-76",
"pmid": "4887042"
},
{
"citation": "JAMA. 1964 Dec 21;190:1071-4",
"pmid": "14212293"
},
{
"citation": "Pharmacotherapy. 1984 Mar-Apr;4(2):99-100",
"pmid": "6718257"
},
{
"citation": "Br Med J. 1974 Jun 8;2(5918):560",
"pmid": "4276108"
},
{
"citation": "Br Med J. 1969 Mar 1;1(5643):539-40",
"pmid": "5764701"
},
{
"citation": "Am J Med Sci. 1979 Jan-Feb;277(1):49-56",
"pmid": "425999"
},
{
"citation": "N Engl J Med. 1971 Apr 15;284(15):878-81",
"pmid": "5549830"
},
{
"citation": "Med Toxicol. 1987 Mar-Apr;2(2):112-60",
"pmid": "3553833"
},
{
"citation": "Br Med J. 1975 Mar 15;1(5958):595-8",
"pmid": "1125623"
},
{
"citation": "Br Med J (Clin Res Ed). 1983 Jan 15;286(6360):199-202",
"pmid": "6401528"
},
{
"citation": "Eur J Clin Pharmacol. 1980 Jan;17(1):25-31",
"pmid": "7371696"
},
{
"citation": "J Epidemiol Community Health. 1981 Mar;35(1):25-31",
"pmid": "7264530"
},
{
"citation": "Br Med J (Clin Res Ed). 1983 Feb 12;286(6364):544-7",
"pmid": "6402143"
},
{
"citation": "Can Med Assoc J. 1967 Dec 9;97(24):1450-7",
"pmid": "6061609"
},
{
"citation": "Lancet. 1973 Dec 1;2(7840):1232-4",
"pmid": "4128561"
},
{
"citation": "JAMA. 1971 Apr 19;216(3):467-72",
"pmid": "5107928"
},
{
"citation": "Ann Intern Med. 1964 Jan;60:100-10",
"pmid": "14106730"
},
{
"citation": "Br Med J (Clin Res Ed). 1983 Feb 5;286(6363):458-60",
"pmid": "6401562"
}
] | false | eng | Med Toxicol Adverse Drug Exp | 8709214 | 0113-5244 | New Zealand | [] | "2024-08-13T08:46:10.548831Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
Abnormal calcium handling by perifused pancreatic islets from neonatal streptozotocin diabetic model rats. | 36(9) | 827-33 | To elucidate the mechanism of impaired insulin release in case of non-insulin-dependent diabetes (NIDDM), we investigated insulin release and 45Ca++ efflux from perifused islets obtained from neonatal streptozotocin diabetic model rats. The model rats were prepared by the intraperitoneal administration of 65 mg/kg streptozotocin (STZ) to neonatal males. Rats treated with STZ did not differ from controls in body weight from 1 week to 16 weeks. The model rats had significant hyperglycemia both in the fasting state and after intraperitoneal administration of 2 g/kg glucose. Although the diameter of the islets from the model rats was not significantly different from that of controls, immunoreactivity to anti-insulin was slightly diminished, and degranulation was slightly observed in B-cells. Insulin content was reduced to 45.6% of the control. Insulin release from the perifused islets of STZ-treated rats responded little to 16.7 mmol/L glucose, but normally to 20 mmol/L arginine in the presence of 5.5 mmol/L glucose. In experiments to test the 45Ca++ efflux from the perifused islets prelabeled with 45Ca++, a rise of 45Ca++ efflux concomitant with the second phase of insulin release from the islets of the model rats was inhibited although a sharp increase of 45Ca++ efflux concomitant with the first phase of insulin release was maintained. 45Ca++ uptake for 30 minutes was reduced in the islets from the model rats in the basal and stimulated state of insulin secretion although the incremental 45Ca++ uptake was similar. It is possible that the abnormal calcium handling in pancreatic B-cells may be one of the causes of defect in insulin release in our model rats.(ABSTRACT TRUNCATED AT 250 WORDS) | Metabolism: clinical and experimental | [
{
"affiliation": "",
"forename": "N",
"identifier": "",
"initials": "N",
"lastname": "Hashimoto"
},
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Kanatsuka"
},
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Makino"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Sakurada"
},
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Iwaoka"
},
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Yoshida"
},
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Horie"
}
] | 1987-09 | 3306276 | D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism; D001120:Arginine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D005947:Glucose / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010477:Perfusion; D051381:Rats; D011919:Rats, Inbred Strains | D016428:Journal Article | D007328:Insulin; D001120:Arginine; D005947:Glucose; D002118:Calcium | 10.1016/0026-0495(87)90089-8 | [] | false | eng | Metabolism | 0375267 | 0026-0495 | United States | [] | "2024-08-13T08:46:10.551151Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Selective in situ pancreatic perfusion via chronic in vivo celiac artery catheterization. | 36(9) | 846-50 | A new technique to catheterize the celiac artery has been developed. This has opened the possibility for direct in vivo, in situ study of pancreatic endocrine cell function in a conscious experimental animal. The catheter is small, soft and placed without arterial ligation so that celiac artery, hepatic, splenic, and pancreatic blood flows were essentially not compromised. Arterial vessel integrity, absence of inflammation, and thrombosis as well as catheter patency were achieved for periods exceeding eight months. Metabolically and hormonally, the presence of the catheter had no effect on the fasting status. However, we found somewhat lower glucose levels and higher insulin levels in the response to oral glucose challenges after catheterization, but these differences were statistically not significant. Glucose loads of 50 mg/kg (0.75 g) administered directly to the pancreas via the celiac artery produced peak insulin levels similar to peripheral glucose loads some tenfold larger. We suggest that this technique may be useful to selectively study the first-pass pancreatic response to a variety of hormones, drugs or metabolic substrates. | Metabolism: clinical and experimental | [
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Kubota"
},
{
"affiliation": "",
"forename": "T",
"identifier": "",
"initials": "T",
"lastname": "Strack"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Schulz"
},
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Bahoric"
},
{
"affiliation": "",
"forename": "A M",
"identifier": "",
"initials": "AM",
"lastname": "Albisser"
}
] | 1987-09 | 3306278 | D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002408:Catheters, Indwelling; D002445:Celiac Artery / Q000000981:diagnostic imaging; D004285:Dogs; D005215:Fasting; D005947:Glucose / Q000008:administration & dosage; D005951:Glucose Tolerance Test / Q000379:methods; D007269:Injections, Intra-Arterial; D007328:Insulin / Q000097:blood; D007515:Islets of Langerhans / Q000502:physiology*; D008297:Male; D010477:Perfusion / Q000379:methods*; D011859:Radiography | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't | D001786:Blood Glucose; D007328:Insulin; D005947:Glucose | 10.1016/0026-0495(87)90092-8 | [] | false | eng | Metabolism | 0375267 | 0026-0495 | United States | [] | "2024-08-13T08:46:10.552226Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Association of serum lipids and lipoproteins with plasma C-peptide concentration in non-insulin-dependent diabetic and non-diabetic subjects. | 36(9) | 840-5 | Serum lipids and lipoproteins were studied in 149 non-insulin-dependent diabetic subjects treated with diet or oral drugs (75 men, 74 women) and in 101 nondiabetic control subjects (49 men, 52 women) in relation to endogenous insulin secretion capacity measured by plasma C-peptide response to intravenous glucagon. Serum HDL- and HDL2-cholesterol concentrations were lower and VLDL-cholesterol and total and VLDL-triglyceride concentrations higher in subjects with high C-peptide response (above the median) than in subjects with low C-peptide response (lower or equal to median) both in diabetic and control subjects of both sexes. Adjustment for the effect of obesity abolished these differences in serum lipids and lipoproteins in diabetic subjects but not in control subjects. This may indicate that obesity has stronger influence on serum lipids in diabetic subjects than in nondiabetic subjects. | Metabolism: clinical and experimental | [
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Sarlund"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Laakso"
},
{
"affiliation": "",
"forename": "K",
"identifier": "",
"initials": "K",
"lastname": "Pyörälä"
},
{
"affiliation": "",
"forename": "I",
"identifier": "",
"initials": "I",
"lastname": "Penttilä"
}
] | 1987-09 | 3306277 | D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood*; D003920:Diabetes Mellitus / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D005260:Female; D005934:Glucagon; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't | D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D005934:Glucagon | 10.1016/0026-0495(87)90091-6 | [] | false | eng | Metabolism | 0375267 | 0026-0495 | United States | [] | "2024-08-13T08:46:10.553424Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Net hepatic lactate balance following mixed meal feeding in the four-day fasted conscious dog. | 36(9) | 856-62 | The present experiments were undertaken to determine whether four days of fasting and marked hepatic glycogen depletion would alter the effect of mixed meal feeding on net hepatic lactate balance in the conscious dog. Dogs were fasted for four days and were then fed a mixed meal over a ten-minute period. Net hepatic glucose and lactate balance were monitored for the next eight hours using the A-V difference technique. The arterial plasma glucose level rose to a maximum of 121 +/- 3 mg/dL three hours after feeding and then decreased. Net hepatic glucose output declined to 0.44 +/- 0.44 mg/kg/min but the liver never became a net consumer of glucose. The arterial blood lactate level rose from 678 +/- 71 to 1000 +/- 158 mumol/L as the liver switched from net lactate uptake (12.2 +/- 2.0 mumol/kg/min) to net lactate production (4.3 +/- 1.7 mumol/kg/min). Over the course of the eight-hour postprandial period 25 g of glycogen were deposited in the liver. The net hepatic uptake of the gluconeogenic amino acids rose from 6.1 +/- 1.2 mumol/kg/min to a peak of 15.4 +/- 4.3 mumol/kg/min one hour after feeding. Net hepatic uptake of glycerol fell from 3.0 +/- 0.3 mumol/kg/min to an average of 1.5 +/- 0.4 mumol/kg/min. The plasma insulin level increased from 13 +/- 2 microU/mL at 3.5 hours and fell to 32 +/- 7 microU/mL by 8 hours. The plasma glucagon level rose from 22 +/- 3 pg/mL to 93 +/- 12 pg/mL 1.5 hours after feeding and fell to 68 +/- 6 pg/mL 8 hours after feeding.(ABSTRACT TRUNCATED AT 250 WORDS) | Metabolism: clinical and experimental | [
{
"affiliation": "",
"forename": "M A",
"identifier": "",
"initials": "MA",
"lastname": "Davis"
},
{
"affiliation": "",
"forename": "P E",
"identifier": "",
"initials": "PE",
"lastname": "Williams"
},
{
"affiliation": "",
"forename": "A D",
"identifier": "",
"initials": "AD",
"lastname": "Cherrington"
}
] | 1987-09 | 3306279 | D000596:Amino Acids / Q000378:metabolism; D000818:Animals; D001806:Blood Urea Nitrogen; D004285:Dogs; D005215:Fasting; D005260:Female; D005502:Food; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000378:metabolism; D005990:Glycerol / Q000378:metabolism; D007328:Insulin / Q000097:blood; D007773:Lactates / Q000378:metabolism*; D019344:Lactic Acid; D008099:Liver / Q000378:metabolism*; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male | D016428:Journal Article | D000596:Amino Acids; D007328:Insulin; D007773:Lactates; D008112:Liver Glycogen; D019344:Lactic Acid; D005934:Glucagon; D005947:Glucose; D005990:Glycerol | 10.1016/0026-0495(87)90094-1 | [] | false | eng | Metabolism | 0375267 | 0026-0495 | United States | [] | "2024-08-13T08:46:10.554510Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Role of extracorporeal drug removal in acute theophylline poisoning. A review. | 2(4) | 294-308 | Theophylline, with its narrow therapeutic margin, is a common cause of iatrogenic and deliberate overdose. Most cases of self-poisoning are with sustained release preparations, with peak concentrations occurring up to 12 or more hours after overdose. Toxic symptoms are often seen at concentrations above 15 mg/L. Theophylline is metabolised within the cytochrome P-450 system, with an average total body clearance of 50 to 60 ml/min. Clearance is, however, affected by many factors such as other drugs or disease, and in overdose zero order kinetics may result in prolonged half-lives. Toxicity is characterised by agitation, tremor, nausea, vomiting, abdominal pains, seizures, and tachyarrhythmias. Hypokalaemia and metabolic acidosis are more profound in acute toxicity, and hypercalcaemia is usually present. Seizures occur at lower concentrations after chronic over-medication than after acute overdose. Gastric lavage should be performed in all patients presenting early, and an oral multiple dose charcoal regimen started with 50 to 100g charcoal, repeating with 50g doses and checking theophylline concentrations at 2- to 4-hour intervals. Multiple dose charcoal can be expected to double the clearance of theophylline, being as effective as a haemodialysis. Of the invasive techniques available, charcoal haemoperfusion is the most effective, increasing clearance 4- to 6-fold. Supportive care is particularly important. The aggressive supplementation of potassium, treatment of emesis with droperidol and ranitidine, and treatment of tachyarrhythmias and hypotension (possibly with propranolol), together with oral multiple dose charcoal may obviate the need for haemoperfusion. Seizures suggest increased morbidity and mortality. Charcoal haemoperfusion should be considered if plasma concentrations are greater than 100 mg/L in an acute intoxication or greater than 60 mg/L in a chronic intoxication. The decision to haemoperfuse should not be based on plasma concentrations alone, but an overall evaluation of the patient's laboratory and clinical status. | Medical toxicology and adverse drug experience | [
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Heath"
},
{
"affiliation": "",
"forename": "K",
"identifier": "",
"initials": "K",
"lastname": "Knudsen"
}
] | 1987 | 3306269 | D001803:Blood Transfusion; D006464:Hemoperfusion; D006801:Humans; D006435:Renal Dialysis; D013806:Theophylline / Q000378:metabolism / Q000506:poisoning* | D016428:Journal Article; D016454:Review | D013806:Theophylline | 10.1007/BF03259871 | [
{
"citation": "Ann Intern Med. 1979 Aug;91(2):301-4",
"pmid": "111596"
},
{
"citation": "Dev Toxicol Environ Sci. 1986;12:339-45",
"pmid": "3549235"
},
{
"citation": "JAMA. 1979 Jun 15;241(24):2613-5",
"pmid": "439357"
},
{
"citation": "Lancet. 1985 Jan 19;1(8421):146-7",
"pmid": "2857219"
},
{
"citation": "Br Med J. 1979 Nov 3;2(6198):1114",
"pmid": "519320"
},
{
"citation": "Am J Kidney Dis. 1984 Mar;3(5):321-38",
"pmid": "6367439"
},
{
"citation": "Anaesthesia. 1984 Aug;39(8):806-9",
"pmid": "6383113"
},
{
"citation": "Chest. 1985 Mar;87(3):325-9",
"pmid": "3971756"
},
{
"citation": "JAMA. 1976 May 3;235(18):1983-6",
"pmid": "946508"
},
{
"citation": "Gastroenterology. 1981 Jul;81(1):19-21",
"pmid": "7239117"
},
{
"citation": "Clin Pharmacol Ther. 1983 Mar;33(3):351-4",
"pmid": "6337763"
},
{
"citation": "West J Med. 1984 Oct;141(4):485-90",
"pmid": "6506685"
},
{
"citation": "Clin Pharmacokinet. 1979 Nov-Dec;4(6):449-59",
"pmid": "519931"
},
{
"citation": "Pediatrics. 1983 Nov;72(5):746-7",
"pmid": "6634285"
},
{
"citation": "Ned Tijdschr Geneeskd. 1977 May 28;121(22):896-901",
"pmid": "876414"
},
{
"citation": "JAMA. 1978 Aug 4;240(5):474-5",
"pmid": "96282"
},
{
"citation": "J Clin Hosp Pharm. 1984 Sep;9(3):147-60",
"pmid": "6386886"
},
{
"citation": "Clin Pharmacokinet. 1979 Sep-Oct;4(5):329-54",
"pmid": "389527"
},
{
"citation": "Pediatrics. 1980 Apr;65(4):811-4",
"pmid": "7367091"
},
{
"citation": "Clin Pharmacokinet. 1978 Jul-Aug;3(4):267-93",
"pmid": "354635"
},
{
"citation": "Am J Dis Child. 1980 Jan;134(1):39-41",
"pmid": "7350785"
},
{
"citation": "Acta Clin Belg. 1981;36(1):30-6",
"pmid": "7293639"
},
{
"citation": "Lancet. 1985 Jun 22;1(8443):1451-2",
"pmid": "2861396"
},
{
"citation": "Dev Pharmacol Ther. 1980;1(1):26-30",
"pmid": "7438965"
},
{
"citation": "J Pediatr. 1979 Feb;94(2):314-6",
"pmid": "762633"
},
{
"citation": "Ann Intern Med. 1981 Jul;95(1):68-9",
"pmid": "7247131"
},
{
"citation": "Eur J Respir Dis Suppl. 1980;109:54-60",
"pmid": "6934088"
},
{
"citation": "Pediatrics. 1983 Apr;71(4):615-9",
"pmid": "6835742"
},
{
"citation": "Chest. 1985 Nov;88(5):749-50",
"pmid": "4053717"
},
{
"citation": "N Engl J Med. 1979 Jan 4;300(1):24-6",
"pmid": "758157"
},
{
"citation": "J Pediatr. 1977 Nov;91(5):820-4",
"pmid": "909026"
},
{
"citation": "Clin Pharmacol Ther. 1983 Nov;34(5):663-6",
"pmid": "6627827"
},
{
"citation": "Hum Toxicol. 1986 Jul;5(4):255-63",
"pmid": "3733116"
},
{
"citation": "Am J Physiol. 1974 Jul;227(1):194-9",
"pmid": "4843371"
},
{
"citation": "Med Toxicol. 1986 Mar-Apr;1(2):142-53",
"pmid": "3784840"
},
{
"citation": "Ulster Med J. 1984;53(2):159-61",
"pmid": "6531834"
},
{
"citation": "Br Med J. 1980 May 10;280(6224):1167",
"pmid": "7388449"
},
{
"citation": "J Pediatr. 1986 Oct;109(4):719-22",
"pmid": "3761093"
},
{
"citation": "Am Rev Respir Dis. 1983 Nov;128(5):820-2",
"pmid": "6638669"
},
{
"citation": "Br Med J (Clin Res Ed). 1982 Mar 27;284(6320):939-40",
"pmid": "6175373"
},
{
"citation": "N C Med J. 1984 Jul;45(7):457-9",
"pmid": "6589495"
},
{
"citation": "Int J Artif Organs. 1983 Sep;6(5):225-6",
"pmid": "6642716"
},
{
"citation": "Presse Med. 1983 Sep 17;12(32):1998-9",
"pmid": "6225107"
},
{
"citation": "J Int Med Res. 1981;9(3):222-5",
"pmid": "7238997"
},
{
"citation": "Br Med J (Clin Res Ed). 1982 Mar 27;284(6320):943",
"pmid": "6802360"
},
{
"citation": "Clin Toxicol. 1980 Nov;17(4):515-27",
"pmid": "7006892"
},
{
"citation": "Clin Pharmacokinet. 1979 Jul-Aug;4(4):320-1",
"pmid": "487687"
},
{
"citation": "Pediatrics. 1984 Jun;73(6):878",
"pmid": "6728592"
},
{
"citation": "Am J Kidney Dis. 1981 Jul;1(1):24-6",
"pmid": "7331999"
},
{
"citation": "J Clin Pharmacol. 1979 Apr;19(4):219-26",
"pmid": "438357"
},
{
"citation": "J Anal Toxicol. 1982 Mar-Apr;6(2):62-3",
"pmid": "7098449"
},
{
"citation": "Am J Emerg Med. 1985 Sep;3(5):386-94",
"pmid": "4041188"
},
{
"citation": "Hum Toxicol. 1985 Mar;4(2):127-34",
"pmid": "4007877"
},
{
"citation": "Chest. 1985 Aug;88(2 Suppl):103S-111S",
"pmid": "3893922"
},
{
"citation": "Br Med J (Clin Res Ed). 1982 Jun 5;284(6330):1709",
"pmid": "6805670"
},
{
"citation": "J Clin Pharmacol. 1982 Jan;22(1):59-64",
"pmid": "7061727"
},
{
"citation": "Br Med J (Clin Res Ed). 1986 Nov 22;293(6558):1321-2",
"pmid": "2878703"
},
{
"citation": "Am J Emerg Med. 1985 Sep;3(5):408-11",
"pmid": "4041191"
},
{
"citation": "Lancet. 1985 Apr 20;1(8434):932-3",
"pmid": "2858780"
},
{
"citation": "J Pharmacokinet Biopharm. 1982 Aug;10(4):437-54",
"pmid": "7153874"
},
{
"citation": "Lakartidningen. 1982 Mar 3;79(9):745-6",
"pmid": "7098680"
},
{
"citation": "Br Med J (Clin Res Ed). 1984 Jun 16;288(6433):1835",
"pmid": "6428570"
},
{
"citation": "JAMA. 1983 Jun 17;249(23):3176",
"pmid": "6854843"
},
{
"citation": "Lancet. 1985 Jul 20;2(8447):160-1",
"pmid": "2862356"
},
{
"citation": "Am J Emerg Med. 1986 May;4(3):205-9",
"pmid": "2870722"
},
{
"citation": "Lancet. 1985 Mar 2;1(8427):520-1",
"pmid": "2857884"
},
{
"citation": "Med Toxicol. 1986 May-Jun;1(3):169-91",
"pmid": "3537617"
},
{
"citation": "Ann Intern Med. 1978 Apr;88(4):516-7",
"pmid": "637435"
},
{
"citation": "Ann Intern Med. 1986 Sep;105(3):386-7",
"pmid": "3740677"
},
{
"citation": "Lancet. 1983 Sep 10;2(8350):618",
"pmid": "6136759"
},
{
"citation": "Ann Intern Med. 1975 Jun;82(6):784-7",
"pmid": "237450"
},
{
"citation": "J Pharmacol Exp Ther. 1982 Jun;221(3):656-63",
"pmid": "7086679"
},
{
"citation": "Br Med J (Clin Res Ed). 1984 May 19;288(6429):1497",
"pmid": "6426617"
},
{
"citation": "J Toxicol Clin Toxicol. 1982 Jul;19(5):433-44",
"pmid": "7175988"
},
{
"citation": "J Pediatr. 1983 Dec;103(6):1004",
"pmid": "6644410"
},
{
"citation": "Acta Med Scand. 1986;219(4):425-7",
"pmid": "3716886"
},
{
"citation": "Eur J Clin Pharmacol. 1983;24(4):557-62",
"pmid": "6134626"
},
{
"citation": "Ann Intern Med. 1986 Jul;105(1):52-4",
"pmid": "3013062"
},
{
"citation": "Dev Pharmacol Ther. 1980;1(1):16-25",
"pmid": "7438964"
},
{
"citation": "Ann Intern Med. 1985 Jun;102(6):766-9",
"pmid": "2986507"
},
{
"citation": "JAMA. 1982 Oct 8;248(14):1742",
"pmid": "6811769"
},
{
"citation": "Ann Intern Med. 1984 Oct;101(4):457-62",
"pmid": "6383163"
},
{
"citation": "JAMA. 1984 Jun 15;251(23):3130-1",
"pmid": "6726987"
},
{
"citation": "Am J Med. 1984 May;76(5):854-60",
"pmid": "6720731"
},
{
"citation": "Clin Pharmacol Ther. 1984 Mar;35(3):402-8",
"pmid": "6697647"
},
{
"citation": "Crit Care Med. 1984 Feb;12(2):113-4",
"pmid": "6697727"
},
{
"citation": "Hum Toxicol. 1986 Jan;5(1):11-4",
"pmid": "3949363"
},
{
"citation": "Clin Toxicol. 1978;13(4):505-11",
"pmid": "747908"
},
{
"citation": "Arch Intern Med. 1984 Mar;144(3):484-6",
"pmid": "6322709"
},
{
"citation": "Drug Intell Clin Pharm. 1983 Nov;17(11):847",
"pmid": "6641510"
},
{
"citation": "Drug Intell Clin Pharm. 1981 Mar;15(3):215",
"pmid": "7274039"
},
{
"citation": "Clin Toxicol. 1980 Nov;17(4):583-602",
"pmid": "7006895"
},
{
"citation": "Lancet. 1983 Sep 10;2(8350):610-3",
"pmid": "6136756"
},
{
"citation": "J Pediatr. 1980 Nov;97(5):825-8",
"pmid": "7431179"
},
{
"citation": "Arch Intern Med. 1984 Apr;144(4):724-7",
"pmid": "6712370"
},
{
"citation": "Clin Toxicol. 1981 Jul;18(7):865-71",
"pmid": "7332642"
},
{
"citation": "Hum Toxicol. 1986 Sep;5(5):341-2",
"pmid": "3770770"
},
{
"citation": "Am J Med. 1983 Jun;74(6):961-6",
"pmid": "6859064"
},
{
"citation": "Br Med J (Clin Res Ed). 1986 Nov 1;293(6555):1143",
"pmid": "3094809"
},
{
"citation": "Clin Pharmacol Ther. 1980 Oct;28(4):463-7",
"pmid": "7408406"
},
{
"citation": "JAMA. 1977 Apr 4;237(14):1466-7",
"pmid": "576640"
},
{
"citation": "J Pediatr. 1983 Mar;102(3):474-6",
"pmid": "6827426"
},
{
"citation": "J Pharm Sci. 1978 Jul;67(7):916-9",
"pmid": "660507"
},
{
"citation": "Acta Med Scand. 1984;216(4):423-6",
"pmid": "6516911"
},
{
"citation": "Clin Pharmacokinet. 1982 Nov-Dec;7(6):465-89",
"pmid": "6761032"
},
{
"citation": "Clin Toxicol. 1977 Dec;11(5):561-7",
"pmid": "608318"
},
{
"citation": "Med Toxicol. 1986 Jan-Feb;1(1):3-11",
"pmid": "3784838"
},
{
"citation": "Ann Intern Med. 1981 Nov;95(5):582-5",
"pmid": "7294546"
},
{
"citation": "Drug Intell Clin Pharm. 1983 Mar;17(3):202-5",
"pmid": "6839945"
},
{
"citation": "J Pharm Sci. 1978 Mar;67(3):426-7",
"pmid": "25327"
},
{
"citation": "Am J Med. 1984 Aug;77(2):A105",
"pmid": "6465168"
},
{
"citation": "J Pediatr. 1986 Sep;109(3):538-42",
"pmid": "3746549"
}
] | false | eng | Med Toxicol Adverse Drug Exp | 8709214 | 0113-5244 | New Zealand | [] | "2024-08-13T08:46:10.557991Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Human blood-brain barrier transferrin receptor. | 36(9) | 892-5 | The kinetics of binding and endocytosis of 125I-human holotransferrin by isolated human brain capillaries was examined using this system as a model of the human blood-brain barrier (BBB). Both binding and endocytosis of the peptide by human brain capillaries was temperature-dependent and the binding was saturated by holotransferrin, but not by insulin, somatostatin, or vasopressin. Scatchard analysis of the binding reaction revealed a dissociation constant of 448 +/- 110 ng/mL (5.6 +/- 1.4 nmol/L) and a maximal binding constant (Ro) of 8.0 +/- 1.5 ng/mg protein. Thus, the affinity and capacity of the BBB transferrin receptor is within the same order of magnitude as the affinity and capacity of the BBB receptors for insulin, insulinlike growth factor-I, or insulinlike growth factor-II. The human brain capillary transferrin receptor was also detected with a mouse monoclonal antibody to the receptor using the avidin/biotin/peroxidase technique. In conclusion, these studies characterize the human BBB transferrin receptor and support the hypothesis that this receptor acts as a transport system which mediates the transcytosis of transferrin-bound iron through the brain capillary endothelial cell in man. | Metabolism: clinical and experimental | [
{
"affiliation": "",
"forename": "W M",
"identifier": "",
"initials": "WM",
"lastname": "Pardridge"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Eisenberg"
},
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Yang"
}
] | 1987-09 | 3306281 | D000328:Adult; D000368:Aged; D001667:Binding, Competitive; D001812:Blood-Brain Barrier; D001921:Brain / Q000098:blood supply; D002196:Capillaries / Q000378:metabolism; D004705:Endocytosis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D066298:In Vitro Techniques; D007444:Inulin / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011990:Receptors, Transferrin / Q000378:metabolism*; D013696:Temperature | D016428:Journal Article; D013487:Research Support, U.S. Gov't, P.H.S. | D011990:Receptors, Transferrin; D007444:Inulin | 10.1016/0026-0495(87)90099-0 | [] | false | eng | Metabolism | 0375267 | 0026-0495 | United States | [
{
"agency": "NIADDK NIH HHS",
"country": "United States",
"grant_acronym": "AM",
"grant_id": "AM-25744"
}
] | "2024-08-13T08:46:10.561219Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Possible role for the glucose-fatty acid cycle in dexamethasone-induced insulin antagonism in rats. | 36(9) | 883-91 | This study was undertaken to elucidate the mechanism(s) involved in glucocorticoid-induced insulin antagonism. Male Sprague-Dawley rats (200 to 210 g) were injected with 1 mg/kg dexamethasone-phosphate (Dex) or the vehicle every other day for 10 days. Two days after the last injection, fasted anesthetized animals were infused (per kg body weight per min) with 8 mg glucose, 5 mU porcine insulin and 1.4 micrograms somatostatin with blood sampling before, and at 10 min intervals between 90 and 130 min after the pancreatic suppression test was begun. At the end of the test, abdominal muscle was quickly freeze-clamped and the substrate and products of the rate-determining reactions of glycolysis and glycogenesis were measured. Dex-treated rats had higher basal (0 min) and steady-state levels (90-130 min) of both glucose and insulin signifying insulin antagonism. The pattern of muscle tissue metabolites revealed no free intracellular glucose in either group and concentrations of all other metabolites in the Dex-treated rats were less than those in the control animals (except for a small increase in glycogen). These results suggest a site of insulin antagonism between (and including) insulin binding and glucose transport. Further studies in the Dex-treated rats revealed normal: a) insulin binding to freshly isolated hepatocytes; b) basal and insulin-stimulated xylose transport in soleus muscle; c) basal and insulin-stimulated glucose uptake in hemidiaphragms. These normal in-vitro results suggested that a circulating factor may be responsible. Repeat pancreatic suppression tests in the Dex-treated rats revealed blunted suppression of serum FFA concentrations.(ABSTRACT TRUNCATED AT 250 WORDS) | Metabolism: clinical and experimental | [
{
"affiliation": "",
"forename": "N",
"identifier": "",
"initials": "N",
"lastname": "Venkatesan"
},
{
"affiliation": "",
"forename": "M B",
"identifier": "",
"initials": "MB",
"lastname": "Davidson"
},
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Hutchinson"
}
] | 1987-09 | 3306280 | D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism*; D007328:Insulin / Q000378:metabolism; D007329:Insulin Antagonists; D007515:Islets of Langerhans / Q000187:drug effects; D008066:Lipolysis / Q000187:drug effects; D008099:Liver / Q000378:metabolism; D008297:Male; D009132:Muscles / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D014994:Xylose / Q000378:metabolism | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't | D005230:Fatty Acids, Nonesterified; D007328:Insulin; D007329:Insulin Antagonists; D003907:Dexamethasone; D014994:Xylose; D005947:Glucose | 10.1016/0026-0495(87)90098-9 | [] | false | eng | Metabolism | 0375267 | 0026-0495 | United States | [] | "2024-08-13T08:46:10.562318Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review. | 36(9) | 900-17 | This report summarizes the current concepts regarding the in vitro and in vivo modulation of the enzymic activity of HMG-CoA reductase and mevalonate formation in rat and human liver, as well as in cultured fibroblasts from normal and familial hypercholesterolemic subjects. Three separate mechanisms for the short-term modulation of hepatic HMG-CoA reductase activity by covalent phosphorylation have been described. These mechanisms involved three separate specific kinase systems including reductase kinase, protein kinase C, and a Ca+2, calmodulin-dependent kinase. The conceptual schemes presented in this report will provide a basis for future research as well as an overview for improved understanding of the complex and multifaceted short-term regulation of this key enzyme in the biosynthetic pathways of mevalonate, ubiquinones, dolichols, isopentenyl-tRNAs, and cholesterol. | Metabolism: clinical and experimental | [
{
"affiliation": "",
"forename": "Z H",
"identifier": "",
"initials": "ZH",
"lastname": "Beg"
},
{
"affiliation": "",
"forename": "J A",
"identifier": "",
"initials": "JA",
"lastname": "Stonik"
},
{
"affiliation": "",
"forename": "H B",
"identifier": "",
"initials": "HB",
"lastname": "Brewer"
}
] | 1987-09 | 3306282 | D055372:AMP-Activated Protein Kinases; D000818:Animals; D002118:Calcium / Q000502:physiology; D002147:Calmodulin / Q000502:physiology; D002784:Cholesterol / Q000378:metabolism; D005347:Fibroblasts / Q000201:enzymology; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism*; D008099:Liver / Q000201:enzymology; D008798:Mevalonic Acid / Q000096:biosynthesis; D009097:Multienzyme Complexes / Q000378:metabolism*; D010766:Phosphorylation; D011493:Protein Kinase C / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases; D051381:Rats | D016428:Journal Article; D016454:Review | D002147:Calmodulin; D009097:Multienzyme Complexes; D002784:Cholesterol; D006903:Hydroxymethylglutaryl CoA Reductases; D011494:Protein Kinases; D017346:Protein Serine-Threonine Kinases; D011493:Protein Kinase C; D055372:AMP-Activated Protein Kinases; D008798:Mevalonic Acid; D002118:Calcium | 10.1016/0026-0495(87)90101-6 | [] | false | eng | Metabolism | 0375267 | 0026-0495 | United States | [] | "2024-08-13T08:46:10.563576Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Elastin: an overview. | 144() | 172-96 | Methods in enzymology | [
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Rosenbloom"
}
] | 1987 | 3306283 | D000818:Animals; D004549:Elastin / Q000235:genetics / Q000302:isolation & purification; D005109:Extracellular Matrix / Q000378:metabolism / Q000648:ultrastructure*; D005796:Genes; D006801:Humans; D010802:Phylogeny; D014333:Tropoelastin / Q000302:isolation & purification | D003160:Comparative Study; D016428:Journal Article; D013487:Research Support, U.S. Gov't, P.H.S.; D016454:Review | D014333:Tropoelastin; D004549:Elastin | 10.1016/0076-6879(87)44178-5 | [] | false | eng | Methods Enzymol | 0212271 | 0076-6879 | United States | [
{
"agency": "NIADDK NIH HHS",
"country": "United States",
"grant_acronym": "AM",
"grant_id": "AM-19616"
},
{
"agency": "NIADDK NIH HHS",
"country": "United States",
"grant_acronym": "AM",
"grant_id": "AM-20553"
},
{
"agency": "NIDCR NIH HHS",
"country": "United States",
"grant_acronym": "DE",
"grant_id": "DE-02623"
}
] | "2024-08-13T08:46:10.564303Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Immunology of elastin. | 144() | 246-59 | Methods in enzymology | [
{
"affiliation": "",
"forename": "D S",
"identifier": "",
"initials": "DS",
"lastname": "Wrenn"
},
{
"affiliation": "",
"forename": "R P",
"identifier": "",
"initials": "RP",
"lastname": "Mecham"
}
] | 1987 | 3306284 | D000818:Animals; D000906:Antibodies; D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex / Q000032:analysis; D003429:Cross Reactions; D003895:Desmosine / Q000032:analysis; D004549:Elastin / Q000032:analysis* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005455:Fluorescent Antibody Technique; D007118:Immunoassay / Q000379:methods; D011863:Radioimmunoassay / Q000379:methods | D016428:Journal Article; D013487:Research Support, U.S. Gov't, P.H.S. | D000906:Antibodies; D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D003895:Desmosine; D004549:Elastin | 10.1016/0076-6879(87)44182-7 | [] | false | eng | Methods Enzymol | 0212271 | 0076-6879 | United States | [
{
"agency": "NHLBI NIH HHS",
"country": "United States",
"grant_acronym": "HL",
"grant_id": "HL-07317"
},
{
"agency": "NHLBI NIH HHS",
"country": "United States",
"grant_acronym": "HL",
"grant_id": "HL-26499"
},
{
"agency": "NHLBI NIH HHS",
"country": "United States",
"grant_acronym": "HL",
"grant_id": "HL-29594"
}
] | "2024-08-13T08:46:10.565289Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Elastin degradation. | 144() | 288-305 | Methods in enzymology | [
{
"affiliation": "",
"forename": "M J",
"identifier": "",
"initials": "MJ",
"lastname": "Banda"
},
{
"affiliation": "",
"forename": "Z",
"identifier": "",
"initials": "Z",
"lastname": "Werb"
},
{
"affiliation": "",
"forename": "J H",
"identifier": "",
"initials": "JH",
"lastname": "McKerrow"
}
] | 1987 | 3306285 | D004549:Elastin / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel / Q000379:methods; D007202:Indicators and Reagents; D010196:Pancreatic Elastase / Q000145:classification / Q000378:metabolism*; D011865:Radioisotope Dilution Technique; D013050:Spectrometry, Fluorescence / Q000379:methods; D014316:Tritium | D016428:Journal Article; D013486:Research Support, U.S. Gov't, Non-P.H.S. | D007202:Indicators and Reagents; D014316:Tritium; D004549:Elastin; D010196:Pancreatic Elastase | 10.1016/0076-6879(87)44184-0 | [] | false | eng | Methods Enzymol | 0212271 | 0076-6879 | United States | [] | "2024-08-13T08:46:10.567151Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
The collagens: an overview and update. | 144() | 3-41 | Methods in enzymology | [
{
"affiliation": "",
"forename": "E J",
"identifier": "",
"initials": "EJ",
"lastname": "Miller"
},
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Gay"
}
] | 1987 | 3306286 | D000818:Animals; D003094:Collagen / Q000145:classification / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism*; D006801:Humans; D046911:Macromolecular Substances; D008970:Molecular Weight; D011347:Procollagen / Q000145:classification | D016428:Journal Article; D016454:Review | D046911:Macromolecular Substances; D011347:Procollagen; D003094:Collagen | 10.1016/0076-6879(87)44170-0 | [] | false | eng | Methods Enzymol | 0212271 | 0076-6879 | United States | [] | "2024-08-13T08:46:10.567793Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Proteoglycans: an overview. | 144() | 305-19 | Methods in enzymology | [
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Heinegård"
},
{
"affiliation": "",
"forename": "Y",
"identifier": "",
"initials": "Y",
"lastname": "Sommarin"
}
] | 1987 | 3306287 | D000818:Animals; D002356:Cartilage / Q000032:analysis*; D002499:Centrifugation, Density Gradient / Q000379:methods; D007202:Indicators and Reagents; D011509:Proteoglycans / Q000302:isolation & purification; D014018:Tissue Distribution | D016428:Journal Article; D016454:Review | D007202:Indicators and Reagents; D011509:Proteoglycans | 10.1016/0076-6879(87)44185-2 | [] | false | eng | Methods Enzymol | 0212271 | 0076-6879 | United States | [] | "2024-08-13T08:46:10.568553Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Catabolism and turnover of proteoglycans. | 144() | 412-9 | Methods in enzymology | [
{
"affiliation": "",
"forename": "C J",
"identifier": "",
"initials": "CJ",
"lastname": "Handley"
},
{
"affiliation": "",
"forename": "M A",
"identifier": "",
"initials": "MA",
"lastname": "Campbell"
}
] | 1987 | 3306288 | D000818:Animals; D002358:Cartilage, Articular / Q000378:metabolism*; D002417:Cattle; D005109:Extracellular Matrix / Q000378:metabolism*; D007700:Kinetics; D009924:Organ Culture Techniques; D011509:Proteoglycans / Q000378:metabolism*; D011865:Radioisotope Dilution Technique; D013431:Sulfates / Q000378:metabolism; D013462:Sulfur Radioisotopes | D016428:Journal Article | D011509:Proteoglycans; D013431:Sulfates; D013462:Sulfur Radioisotopes | 10.1016/0076-6879(87)44190-6 | [] | false | eng | Methods Enzymol | 0212271 | 0076-6879 | United States | [] | "2024-08-13T08:46:10.569405Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Clinical profile of Org OD 14. | Suppl 1() | 3-13 | The clinical profile of Org OD 14 ((7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5 (10)-en-20-yn-3-one) is remarkable in that the compound demonstrates simultaneous weak oestrogenic, androgenic and progestational activity after oral administration to animals. It was therefore studied to evaluate its efficacy in the treatment of the climacteric syndrome. Clinical data demonstrating these combined hormonal effects are reviewed in this paper: Administration of 2.5 mg/day Org OD 14 suppressed gonadotrophins in post-menopausal women and inhibited ovulation in fertile women. In post-menopausal women virtually no endometrial proliferation was induced, only occasional, very slight proliferation being seen. Even after 2 yr of therapy no endometrial hyperplasia was observed. A weak stimulatory effect on the vaginal mucosa was apparent. In addition, Org OD 14 prevented post-menopausal bone loss and alleviated vasomotor climacteric symptoms effectively. It also had a beneficial effect on mood and libido. Org OD 14 was well tolerated. The incidence of side effects (changes in body weight, vaginal bleeding) was low and similar to that with placebo treatment. Extensive safety studies of up to 5 yr duration, including liver function tests and metabolic studies, indicated no untoward effects. It was concluded that Org OD 14 is an effective and safe new preparation for the treatment of climacteric patients. | Maturitas | [
{
"affiliation": "",
"forename": "L",
"identifier": "",
"initials": "L",
"lastname": "Tax"
},
{
"affiliation": "",
"forename": "E M",
"identifier": "",
"initials": "EM",
"lastname": "Goorissen"
},
{
"affiliation": "",
"forename": "P M",
"identifier": "",
"initials": "PM",
"lastname": "Kicovic"
}
] | 1987 | 3306290 | D050260:Carbohydrate Metabolism; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006728:Hormones / Q000097:blood; D006801:Humans; D007700:Kinetics; D050356:Lipid Metabolism; D009652:Norpregnenes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D010024:Osteoporosis / Q000517:prevention & control; D011987:Receptors, Steroid / Q000187:drug effects | D016430:Clinical Trial; D018848:Controlled Clinical Trial; D016428:Journal Article | D006728:Hormones; D009652:Norpregnenes; D011987:Receptors, Steroid; C027385:tibolone | 10.1016/0378-5122(87)90038-7 | [] | false | eng | Maturitas | 7807333 | 0378-5122 | Ireland | [] | "2024-08-13T08:46:10.570284Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. | Suppl 1() | 25-33 | In a randomized, double-blind, placebo-controlled efficacy and safety study of Org OD 14 [(7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one] in 60 post-menopausal women, the effects of treatment on clinical parameters (hot flushes and associated complaints) and laboratory parameters (routine haematology and biochemistry) were evaluated. Assessments were made before treatment and after 1, 3, 6, 9 and 12 mth of therapy (in the case of the laboratory parameters after 6 and 12 mth only). In total, 17 patients dropped out, 6 of whom were on Org OD 14 and 11 on placebo. Clinical parameters were evaluated by means of the Yates test. Org OD 14 had a significantly better effect than placebo on hot flushes and sweating at all stages of assessment. A similar effect, albeit to a lesser extent, was seen on sleeplessness, fatigability, irritability and psychic instability. Serum levels of alkaline phosphatase, triglycerides, high-density lipoprotein cholesterol and phosphate decreased during Org OD 14 treatment. It was concluded that Org OD 14 provides a new, efficient and safe means of treating the post-menopausal syndrome. | Maturitas | [
{
"affiliation": "",
"forename": "L J",
"identifier": "",
"initials": "LJ",
"lastname": "Benedek-Jaszmann"
}
] | 1987 | 3306289 | D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D009652:Norpregnenes / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D012449:Safety; D014280:Triglycerides / Q000097:blood | D016430:Clinical Trial; D016428:Journal Article; D016449:Randomized Controlled Trial | D009652:Norpregnenes; D014280:Triglycerides; C027385:tibolone | 10.1016/0378-5122(87)90040-5 | [] | false | eng | Maturitas | 7807333 | 0378-5122 | Ireland | [] | "2024-08-13T08:46:10.571129Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Use of Org OD 14 for the treatment of climacteric complaints. | Suppl 1() | 49-65 | The effects of treating climacteric complaints in post-menopausal women were studied in an open trial in which Org OD 14, a placebo and no treatment were compared. In addition to the symptomatic effects, clinical and laboratory parameters were also studied. One hundred and twenty-four women who had undergone a natural or surgical menopause completed 4 mth of randomized treatment; 35 received Org OD 14 (2.5 mg/day, per os), 46 a placebo, and 43 no treatment. The mean ages and time in years since menopause were comparable for each group. The parameters were assessed before treatment and after 4 mth. The results in the group treated with Org OD 14 were compared statistically with those for the other two groups using the chi 2 test, Student's t test or analysis of variance. A beneficial effect on clinical parameters was seen following Org OD 14 treatment. The results as regards hot flushes and sweating were significantly better statistically than those in the other groups. Org OD 14 was found to have no effect on the endometrium, breasts, body weight or blood pressure, while vaginal atrophy was slightly improved. Serum levels of total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides and phosphate were slightly reduced by Org OD 14. Liver function tests, clotting factors and the other routine laboratory parameters were not affected by Org OD 14 treatment. It was concluded that Org OD 14 is an effective and safe compound for the treatment of climacteric syndrome. | Maturitas | [
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "De Aloysio"
},
{
"affiliation": "",
"forename": "A G",
"identifier": "",
"initials": "AG",
"lastname": "Fabiani"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Mauloni"
},
{
"affiliation": "",
"forename": "F",
"identifier": "",
"initials": "F",
"lastname": "Bottiglioni"
}
] | 1987 | 3306291 | D002118:Calcium / Q000378:metabolism; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D009652:Norpregnenes / Q000009:adverse effects / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood; D011897:Random Allocation; D008083:beta-Lipotropin / Q000097:blood | D016430:Clinical Trial; D016428:Journal Article; D016449:Randomized Controlled Trial | D008055:Lipids; D009652:Norpregnenes; D010710:Phosphates; D008083:beta-Lipotropin; C027385:tibolone; D002118:Calcium | 10.1016/0378-5122(87)90042-9 | [] | false | eng | Maturitas | 7807333 | 0378-5122 | Ireland | [] | "2024-08-13T08:46:10.573098Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. | Suppl 1() | 67-72 | The effects of a new synthetic steroid Org OD 14 on the haemostatic mechanism were investigated in 60 post-menopausal women, randomly allocated to 12 weeks of treatment with either 2.5 mg/day of Org OD 14 or a placebo in a double-blind, group-comparative study. Assessments were made 2 weeks before and just prior to the start of treatment, at weeks 6 and 12 during treatment, and 2 weeks after its cessation. No significant differences between the two groups were found with regard to prothrombin time, kaolin cephalin clotting time (KCCT), clotting factors VII, VIII and X, white blood count (WBC) or transaminases (ASAT, ALAT). The following statistically significant differences were seen in the Org OD 14 group: higher plasminogen, antithrombin III, haemoglobin, haematocrit and platelet count, and increased fibrinolytic activity on fibrin plates, as well as lower fibrinogen and alkaline phosphatase values. These findings indicate that Org OD 14 displays no adverse effects on coagulation, while changes in fibrinolysis seem to be beneficial for post-menopausal women. | Maturitas | [
{
"affiliation": "",
"forename": "J",
"identifier": "",
"initials": "J",
"lastname": "Cortes-Prieto"
}
] | 1987 | 3306292 | D001777:Blood Coagulation / Q000187:drug effects*; D002979:Climacteric / Q000097:blood / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D009652:Norpregnenes / Q000009:adverse effects* / Q000627:therapeutic use; D011897:Random Allocation | D016430:Clinical Trial; D016428:Journal Article; D016449:Randomized Controlled Trial | D009652:Norpregnenes; C027385:tibolone | 10.1016/0378-5122(87)90043-0 | [] | false | eng | Maturitas | 7807333 | 0378-5122 | Ireland | [] | "2024-08-13T08:46:10.573793Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Adherence to and penetration of cultured cells by an invasive strain of Escherichia coli: an ultrastructural study. | 10(3) | 317-23 | The penetration process of an enteroinvasive strain of Escherichia coli 0124 into HEp-2 cells has been studied by electron microscopy. Bacteria penetrated into cultured cells by a phagocytosis-like mechanism, and multiplied within the vacuoles as well as in the cytoplasmic matrix. On the whole, the infection cycle of EIEC appeared to be similar to that described for Shigella. The stain examined has also been found to elaborate a 40 nm-thick glyocalix, which is probably involved in the recognition of host surface receptors and therefore in the attachment of microorganisms to the cell membrane. | Microbiologica | [
{
"affiliation": "",
"forename": "L",
"identifier": "",
"initials": "L",
"lastname": "Baldassarri"
},
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Caprioli"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Donelli"
}
] | 1987-07 | 3306293 | D001422:Bacterial Adhesion; D002460:Cell Line; D002462:Cell Membrane / Q000382:microbiology; D003593:Cytoplasm / Q000382:microbiology; D004926:Escherichia coli / Q000254:growth & development* / Q000502:physiology / Q000648:ultrastructure; D006801:Humans; D008854:Microscopy, Electron; D010587:Phagocytosis; D014617:Vacuoles / Q000382:microbiology | D016428:Journal Article | [] | false | eng | Microbiologica | 7902903 | 0391-5352 | Italy | [] | "2024-08-13T08:46:10.574841Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
A new chromogenic test for the detection of urokinase in the genus Shigella. | 10(3) | 331-3 | A simple test for detection of urokinase in Shigella is described. The test is performed by suspending a loopful of bacteria in 100 microliters of a buffered 1mM solution of benzoyl-beta-alanyl glycyl-arginyl-4-nitroanilide acetate (Chromozym U). Enzymatic activity is revealed by formation of a yellow colour after 24 h of incubation at 37 degrees C. The test is able to differentiate serotypes of Shigella dysenteriae, Shigella flexneri, Shigella boydii. The results suggest the possibility of including this chromogenic test in the biochemical assay of Shigella genus. | Microbiologica | [
{
"affiliation": "",
"forename": "M F",
"identifier": "",
"initials": "MF",
"lastname": "Massenti"
},
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Nastasi"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Scarlata"
}
] | 1987-07 | 3306294 | D002863:Chromogenic Compounds; D009842:Oligopeptides; D012760:Shigella / Q000145:classification / Q000201:enzymology*; D012761:Shigella boydii / Q000145:classification / Q000201:enzymology; D012762:Shigella dysenteriae / Q000145:classification / Q000201:enzymology; D012763:Shigella flexneri / Q000145:classification / Q000201:enzymology; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis* | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't | D002863:Chromogenic Compounds; D009842:Oligopeptides; C053661:chromozym U; D014568:Urokinase-Type Plasminogen Activator | [] | false | eng | Microbiologica | 7902903 | 0391-5352 | Italy | [] | "2024-08-13T08:46:10.575709Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
A personal history of the progress in contraception during the past 60 years. | 23(7) | 282-5 | Midwife, health visitor & community nurse | [
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Lehfeldt"
}
] | 1987-07 | 3306295 | D003267:Contraception / Q000266:history* / Q000379:methods; D005060:Europe; D005193:Family Planning Services / Q000266:history; D005260:Female; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D008297:Male; D014481:United States | D016456:Historical Article; D016428:Journal Article | [] | false | eng | Midwife Health Visit Community Nurse | 7504096 | 0306-9699 | England | [] | "2024-08-13T08:46:10.576508Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Infant feeding in the Bible. | 23(7) | 309-13 | Midwife, health visitor & community nurse | [] | 1987-07 | 3306296 | D001633:Bible; D001942:Breast Feeding; D005260:Female; D049690:History, Ancient; D006801:Humans; D007227:Infant Nutritional Physiological Phenomena; D007231:Infant, Newborn; D011247:Pregnancy | D016456:Historical Article; D016428:Journal Article | [] | false | eng | Midwife Health Visit Community Nurse | 7504096 | 0306-9699 | England | [] | "2024-08-13T08:46:10.577193Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Comparison of computer-assisted learning with tutorial teaching in a group of first-year dental students. | 21(4) | 305-9 | Two identical groups of first-year dental students were instructed in the pathology of dental caries and periodontitis using computer-assisted learning (CAL) or tutorial teaching (TT). A cross-over arrangement, in which the first group was taught about dental caries by CAL and periodontitis by TT and the second group in the reverse order, allowed comparison of the two methods. The comparison included a knowledge test and completion of a questionnaire. CAL and TT were equally effective as far as acquisition of knowledge was concerned. Students felt pressurized with CAL and had problems with note-taking. They liked a teacher to be present. Nevertheless, CAL was an acceptable method of instruction and was more economical, in terms of staff involvement, than TT. | Medical education | [
{
"affiliation": "",
"forename": "R S",
"identifier": "",
"initials": "RS",
"lastname": "Levine"
},
{
"affiliation": "",
"forename": "J H",
"identifier": "",
"initials": "JH",
"lastname": "Jones"
},
{
"affiliation": "",
"forename": "C",
"identifier": "",
"initials": "C",
"lastname": "Morgan"
}
] | 1987-07 | 3306297 | D003194:Computer-Assisted Instruction; D004497:Education, Dental; D004739:England; D006801:Humans; D013663:Teaching / Q000379:methods* | D003160:Comparative Study; D016428:Journal Article | 10.1111/j.1365-2923.1987.tb00368.x | [] | false | eng | Med Educ | 7605655 | 0308-0110 | England | [] | "2024-08-13T08:46:10.579017Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
The clinical effects of mixing short- and intermediate-acting insulins in the treatment of non-insulin-dependent diabetes. | 146(12) | 621-3, 627 | Premixing short- and intermediate-acting insulins in one syringe, with refrigerated storage before injection, is practised by some centres in the treatment of older patients with non-insulin-dependent diabetes. Because other studies have reported the loss of the short-acting insulin component after mixing with intermediate-acting insulins, we examined the clinical effect of mixing soluble insulin with lente or isophane insulins in subjects with non-insulin-dependent diabetes. When soluble and lente insulins were mixed in the same syringe and injected immediately, the peak level of insulin was very similar to the peak level after separate injections but occurred at five hours instead of three hours after the injection. As a result, the plasma free-insulin profile over three hours was lower with premixed insulin than after separate injections of the two insulins (incremental insulin area, 88 +/- 20 mU.L-1.h, and 129 +/- 37 mU.L-1.h, respectively; P less than 0.05). This delay in the absorption of soluble insulin caused a greater rise in plasma glucose levels such that the incremental glucose area over eight hours was 25.5 +/- 4.4 mmol.L-1.h for premixed insulin compared with 10.4 +/- 6.2 mmol.L-1.h for separate injections (P less than 0.05). Soluble and isophane insulins had similar absorption profiles whether injected separately or premixed (incremental insulin area, 0 to 3 h, 176 +/- 44 mU.L-1.h and 156 +/- 29 mU.L-1.h, respectively). Our results indicate that the absorption of soluble insulin is delayed when it is mixed with lente insulin but not with isophane insulin. Even in subjects with endogenous insulin secretion, this effect may have clinical importance and should be taken into account when insulin therapy is adjusted for patients with non-insulin-dependent diabetes. | The Medical journal of Australia | [
{
"affiliation": "",
"forename": "J D",
"identifier": "",
"initials": "JD",
"lastname": "Best"
},
{
"affiliation": "",
"forename": "C J",
"identifier": "",
"initials": "CJ",
"lastname": "Ley"
},
{
"affiliation": "",
"forename": "B J",
"identifier": "",
"initials": "BJ",
"lastname": "Strauss"
},
{
"affiliation": "",
"forename": "F P",
"identifier": "",
"initials": "FP",
"lastname": "Alford"
},
{
"affiliation": "",
"forename": "P M",
"identifier": "",
"initials": "PM",
"lastname": "Aitken"
}
] | 1987-06-15 | 3306298 | D000042:Absorption; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007328:Insulin / Q000008:administration & dosage* / Q000097:blood; D007336:Insulin, Isophane / Q000008:administration & dosage; D049528:Insulin, Long-Acting / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012995:Solubility; D013997:Time Factors | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't | D001786:Blood Glucose; D002096:C-Peptide; D004338:Drug Combinations; D007328:Insulin; D049528:Insulin, Long-Acting; D007336:Insulin, Isophane | 10.5694/j.1326-5377.1987.tb120440.x | [] | false | eng | Med J Aust | 0400714 | 0025-729X | Australia | [] | "2024-08-13T08:46:10.580212Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Relevance of the salt-hypertension hypothesis to the community control of hypertension. | 147(1) | 29, 32-5, 37-8 | By applying the Framingham data to the distribution of blood pressure in the Australian population, it can be shown that almost half the morbidity from strokes and ischaemic heart disease that is attributable to blood pressure would be expected to occur in subjects who are "normotensive" by the current World Health Organization (WHO) definition. The steadily increasing risk with every increment of diastolic blood pressure above 70 mmHg supports the contention that the dividing line between "normotension" and "hypertension" is artefactual, and that the basic problem is the tendency for blood pressure levels to rise with age. The rise with age occurs exclusively and invariably in salt-eating societies, and the most promising hypothesis that is awaiting evaluation is that this rise could largely be prevented by the universal adoption of the Australian Recommended Dietary Intake for sodium of 40-100 mmol/day. Two factors that may limit the prophylactic effect of avoiding salt are self-sustaining hypertension and teratogenic hypertension, both of which are seen when rats are fed salt. In Australia and several other countries it is already official policy to recommend a lower intake of salt. Although we support this, we consider that interventions with such massive implications are incomplete without a serious attempt to measure the outcome. Double-blind conditions would be impossible, but a large-scale population-based trial with randomization would be feasible. The first stage of the trial should consist of a campaign of salt reduction in patients with established hypertension, in collaboration with medical practitioners and the food industry, because it is unrealistic to expect good dietary compliance from several thousand "normotensive" persons until those who want to avoid salt are catered for more adequately. | The Medical journal of Australia | [
{
"affiliation": "",
"forename": "T C",
"identifier": "",
"initials": "TC",
"lastname": "Beard"
},
{
"affiliation": "",
"forename": "R F",
"identifier": "",
"initials": "RF",
"lastname": "Heller"
}
] | 1987-07-06 | 3306299 | D001315:Australia; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004039:Diet, Sodium-Restricted; D006291:Health Policy; D006801:Humans; D006973:Hypertension / Q000178:diet therapy / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012306:Risk; D012965:Sodium Chloride / Q000009:adverse effects* | D016430:Clinical Trial; D016428:Journal Article | D012965:Sodium Chloride | 10.5694/j.1326-5377.1987.tb133233.x | [] | false | eng | Med J Aust | 0400714 | 0025-729X | Australia | [] | "2024-08-13T08:46:10.581503Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||
Topical minoxidil for baldness. | 29(749) | 87-8 | The Medical letter on drugs and therapeutics | [] | 1987-09-25 | 3306300 | D000279:Administration, Cutaneous; D000505:Alopecia / Q000188:drug therapy*; D000506:Alopecia Areata / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D008914:Minoxidil / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use* | D016430:Clinical Trial; D016428:Journal Article | D008914:Minoxidil | [] | false | eng | Med Lett Drugs Ther | 2985240R | 0025-732X | United States | [] | "2024-08-13T08:46:10.582384Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
Interleukin-2. | 29(749) | 88-9 | The Medical letter on drugs and therapeutics | [] | 1987-09-25 | 3306301 | D002292:Carcinoma, Renal Cell / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D008545:Melanoma / Q000628:therapy* | D016430:Clinical Trial; D016428:Journal Article | D007376:Interleukin-2 | [] | false | eng | Med Lett Drugs Ther | 2985240R | 0025-732X | United States | [] | "2024-08-13T08:46:10.583152Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
[Experimental evaluation of the methodology for titrating outbred mice to quantitatively measure the rickettsial burden of Ixodoidea ticks]. | 13-6 | Meditsinskaia parazitologiia i parazitarnye bolezni | [
{
"affiliation": "",
"forename": "A P",
"identifier": "",
"initials": "AP",
"lastname": "Pchelkin"
},
{
"affiliation": "",
"forename": "V M",
"identifier": "",
"initials": "VM",
"lastname": "Podboronov"
},
{
"affiliation": "",
"forename": "A A",
"identifier": "",
"initials": "AA",
"lastname": "Pchelkina"
},
{
"affiliation": "",
"forename": "V F",
"identifier": "",
"initials": "VF",
"lastname": "Ignatovich"
}
] | 1987 | 3306302 | D000818:Animals; D001431:Bacteriological Techniques; D051379:Mice; D012281:Rickettsia / Q000302:isolation & purification*; D013987:Ticks / Q000382:microbiology* | D004740:English Abstract; D016428:Journal Article | [] | false | rus | Eksperimental'naia otsenka metodiki titrovaniia na autbrednykh myshakh dlia opredeleniia kolichestvennogo soderzhaniia rikketsiĭ v iksodoidnykh kleshchakh. | Med Parazitol (Mosk) | 0376635 | 0025-8326 | Russia (Federation) | [] | "2024-08-13T08:46:10.583871Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Estimation of tissue parameters derived from reflected ultrasound. | 12(3-4) | 185-95 | We propose a method of estimating two tissue parameters, that is, the reflection coefficient and attenuation coefficient from the reflected ultrasound for the purpose of improving the resolution of ultrasonic images and obtaining information on tissue characterization. The reflection coefficient is estimated by deconvolution technique using Kalman filter taking into account the distortion of the propagating pulse due to the frequency-dependent attenuation. The attenuation is estimated by adaptive processings based upon the criterion function calculated using estimates of the reflection coefficient. Simulated signals are used to investigate the ability of this method. Additionally, actual reflected signals from soft tissues are processed by the method. The results show that the method can be applied in clinical cases. | Medical progress through technology | [
{
"affiliation": "",
"forename": "T",
"identifier": "",
"initials": "T",
"lastname": "Shiina"
},
{
"affiliation": "",
"forename": "K",
"identifier": "",
"initials": "K",
"lastname": "Ikeda"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Saito"
}
] | 1987 | 3306305 | D000818:Animals; D006801:Humans; D008433:Mathematics; D008962:Models, Theoretical; D014465:Ultrasonics / Q000379:methods*; D014463:Ultrasonography | D016428:Journal Article | 10.1007/978-94-009-3361-3_16 | [] | false | eng | Med Prog Technol | 0331260 | 0047-6552 | United States | [] | "2024-08-13T08:46:10.585772Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Recent progress of technology in obstetrics and gynecology, particularly in perinatal medicine in Japan. | 12(3-4) | 197-211 | Medical progress through technology | [
{
"affiliation": "",
"forename": "K",
"identifier": "",
"initials": "K",
"lastname": "Maeda"
}
] | 1987 | 3306306 | D001709:Biotechnology; D004562:Electrocardiography; D005260:Female; D005318:Fetal Heart / Q000502:physiology; D005324:Fetal Movement; D006339:Heart Rate; D006801:Humans; D007231:Infant, Newborn; D007564:Japan; D007743:Labor, Obstetric; D008838:Microcomputers; D008991:Monitoring, Physiologic; D011247:Pregnancy; D011296:Prenatal Diagnosis; D014463:Ultrasonography; D014590:Uterine Contraction | D016428:Journal Article | 10.1007/978-94-009-3361-3_17 | [] | false | eng | Med Prog Technol | 0331260 | 0047-6552 | United States | [] | "2024-08-13T08:46:10.586548Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
[Surgical preparation and technic and perioperative therapy in colorectal interventions: state of the art review]. | 82(15-16) | 532-7 | Medizinische Klinik (Munich, Germany : 1983) | [
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Grundmann"
},
{
"affiliation": "",
"forename": "F",
"identifier": "",
"initials": "F",
"lastname": "Weber"
},
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Pichlmaier"
}
] | 1987-07-17 | 3306307 | D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003108:Colonic Diseases / Q000601:surgery*; D006801:Humans; D011292:Premedication; D011300:Preoperative Care / Q000379:methods*; D012002:Rectal Diseases / Q000601:surgery* | D016428:Journal Article; D016454:Review | D000900:Anti-Bacterial Agents | [] | false | ger | Zur Operationsvorbereitung und -technik sowie perioperativen Therapie bei kolorektalen Eingriffen: Eine Bestandsaufnahme. | Med Klin (Munich) | 8303501 | 0723-5003 | Germany | [] | "2024-08-13T08:46:10.587333Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Intracranial hypertension following craniocerebral trauma]. | 82(15-16) | 538-45, 518 | Medizinische Klinik (Munich, Germany : 1983) | [
{
"affiliation": "",
"forename": "K",
"identifier": "",
"initials": "K",
"lastname": "Geiger"
}
] | 1987-07-17 | 3306308 | D001929:Brain Edema / Q000175:diagnosis*; D001930:Brain Injuries / Q000175:diagnosis*; D006801:Humans; D007427:Intracranial Pressure; D011559:Pseudotumor Cerebri / Q000175:diagnosis* | D016428:Journal Article; D016454:Review | [] | false | ger | Intrakranielle Hypertension nach Schädel-Hirn-Trauma. | Med Klin (Munich) | 8303501 | 0723-5003 | Germany | [] | "2024-08-13T08:46:10.588052Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
History of anesthesia in Jordan. | 9(2) | 141-8 | Middle East journal of anaesthesiology | [
{
"affiliation": "",
"forename": "M S",
"identifier": "",
"initials": "MS",
"lastname": "Takrouri"
}
] | 1987-06 | 3306309 | D000758:Anesthesia / Q000266:history*; D000776:Anesthesiology / Q000266:history; D049668:History, 15th Century; D049672:History, 19th Century; D049673:History, 20th Century; D049691:History, Medieval; D006801:Humans; D007597:Jordan | D016456:Historical Article; D016428:Journal Article; D019477:Portrait | [] | false | eng | Middle East J Anaesthesiol | 8604187 | 0544-0440 | Lebanon | [] | "2024-08-13T08:46:10.589147Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Criteria of brain death--a review. | 9(2) | 149-61 | Middle East journal of anaesthesiology | [
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Kurdi"
},
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Hijazi"
}
] | 1987-06 | 3306310 | D001049:Apnea / Q000175:diagnosis; D001926:Brain Death; D004569:Electroencephalography; D004992:Ethics, Medical; D006801:Humans; D012018:Reflex | D016428:Journal Article; D016454:Review | [] | false | eng | Middle East J Anaesthesiol | 8604187 | 0544-0440 | Lebanon | [] | "2024-08-13T08:46:10.589791Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
A.R.D.S. at King Hussein Medical Centre. | 9(2) | 185-7 | Middle East journal of anaesthesiology | [
{
"affiliation": "",
"forename": "J S",
"identifier": "",
"initials": "JS",
"lastname": "Al-Shanableh"
}
] | 1987-06 | 3306311 | D006801:Humans; D007597:Jordan; D011175:Positive-Pressure Respiration; D012128:Respiratory Distress Syndrome / Q000175:diagnosis / Q000628:therapy | D016428:Journal Article | [] | false | eng | Middle East J Anaesthesiol | 8604187 | 0544-0440 | Lebanon | [] | "2024-08-13T08:46:10.590504Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||||
Pathogenesis of renal stones. | 13(4) | 214-9 | The process of stone formation within the urinary tract involves multiple etiologic factors. Metabolic and/or ion transport abnormalities, either primary or secondary, provide relative solute excess. Multiple changes in the physical chemistry of the urine follow, leading to crystal formation and the potential for stones to occur. The states of saturation, sites and mechanism of crystal retention, and modifiers of crystal formation influence directly this process. In the evaluation of a patient with stones, etiologic factors, be they in the areas of metabolism, ion transport or physical chemistry should be identified. Treatment is then designed to correct these specific abnormalities. The remainder of this article will be devoted to considerations of these principles. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "L H",
"identifier": "",
"initials": "LH",
"lastname": "Smith"
}
] | 1987 | 3306312 | D006801:Humans; D007669:Kidney Calculi / Q000209:etiology* / Q000503:physiopathology / Q000652:urine | D016428:Journal Article; D016454:Review | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.591068Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
[Dynamics of proteolytic enzyme activity in the culture medium of Musca domestica L. housefly larvae]. | 32-4 | Meditsinskaia parazitologiia i parazitarnye bolezni | [
{
"affiliation": "",
"forename": "E L",
"identifier": "",
"initials": "EL",
"lastname": "Zvereva"
},
{
"affiliation": "",
"forename": "E P",
"identifier": "",
"initials": "EP",
"lastname": "Ovsianko"
}
] | 1987 | 3306303 | D000818:Animals; D006793:Houseflies / Q000201:enzymology*; D007814:Larva; D010447:Peptide Hydrolases / Q000378:metabolism* | D004740:English Abstract; D016428:Journal Article | D010447:Peptide Hydrolases | [] | false | rus | Dinamika aktivnosti proteoliticheskikh fermentov v kul'tural'noĭ srede lichinok komnatnoĭ mukhi Musca domestica L. | Med Parazitol (Mosk) | 0376635 | 0025-8326 | Russia (Federation) | [] | "2024-08-13T08:46:10.592841Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
Diet and calcium stones. | 13(4) | 228-34 | Urolithiasis is a worldwide problem which appears to be aggravated by the high-dairy-produce, highly energy-rich and low-fibre diets consumed in most industrialised countries. Together these factors lead to urine with a high risk of calcium oxalate and uric acid crystalluria. Epidemiological evidence points, in particular, to a high-meat protein intake as being the dominant factor within this combination. Such a diet not only increases the risk of stones in the population as a whole through its general effect on the urinary risk factors for stones but also may select out certain individuals who are metabolically more sensitive to this dietary stimulus and who show an exaggerated biochemical response to it. On the basis of epidemiological and biochemical studies, a move towards a more vegetarian, less energy-rich diet would be predicted to reduce the risk of stone formation in the population. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "W G",
"identifier": "",
"initials": "WG",
"lastname": "Robertson"
}
] | 1987 | 3306314 | D002129:Calcium Oxalate / Q000032:analysis*; D004032:Diet; D006801:Humans; D014545:Urinary Calculi / Q000032:analysis / Q000209:etiology* | D016428:Journal Article; D016454:Review | D002129:Calcium Oxalate | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.593410Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Incidence of upper urinary tract stones. | 13(4) | 220-7 | During the last few decades there has been a steady rise of the incidence of upper urinary tract stones in the industrialized countries. Dietary factors, mainly an increased consumption of animal protein, probably explain part of this dramatic change. Little is, however, known how other components of the altered life styles might affect the propensity for stone formation. The prevalence of renal stones, as obtained in postmortem or radiographic studies, is 1-3% without apparent sex differences. In several unselected population surveys the life time risk for males approaches 20% while for females it is 5-10%. The recurrence rate is high and around 50% will experience another stone within 5 years from the onset. The annual incidence is around 1% in males with a peak in the fifth decade. Thus upper urinary tract stones are much more common than is generally appreciated, but most studies of their pathophysiology are only concerned with the small fraction of patients that is investigated in specialized research clinics. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Ljunghall"
}
] | 1987 | 3306313 | D006760:Hospitalization; D006801:Humans; D014545:Urinary Calculi / Q000453:epidemiology* / Q000235:genetics | D016428:Journal Article; D016454:Review | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.593983Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
Primary hyperparathyroidism and idiopathic hypercalciuria. | 13(4) | 235-41 | Primary hyperparathyroidism and idiopathic hypercalciuria are important causes of calcium stone disease. Hypercalcemia is usually the clue to the presence of primary hyperparathyroidism, but a minority of patients are intermittently or persistently normocalcemic. In these patients there appears to be a resistance to the effect of parathyroid hormone on renal calcium transport, to which calcitriol may contribute. Such patients mimic those with idiopathic hypercalciuria, the commonest metabolic cause of stone formation. The pathophysiology of idiopathic hypercalciuria remains controversial, but abnormalities of renal tubule function and disordered vitamin D metabolism are commonly present. The separation into so-called renal and absorptive types does not appear to be of practical importance, since thiazide diuretics provide effective prophylaxis regardless of type. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Halabé"
},
{
"affiliation": "",
"forename": "R A",
"identifier": "",
"initials": "RA",
"lastname": "Sutton"
}
] | 1987 | 3306315 | D002118:Calcium / Q000652:urine*; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications* / Q000652:urine | D016428:Journal Article; D016454:Review | D002118:Calcium | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.594599Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Envelope amplitude analysis following narrow-band filtering: a technique for ultrasonic tissue characterization. | 14(4) | 627-32 | Ultrasonic waveforms backscattered from tissue simulating phantoms and from normal and cirrhotic human livers in vivo were digitized to a standard dynamic range prior to envelope detection and determination of envelope amplitude distributions. For 11 individual narrow-band Gaussian-shaped filters of -6 dB bandwidth 200 kHz, and of center frequencies from 2 to 4 MHz, envelope amplitude distributions were plotted and mean values of the values distributions computed. Analysis of data was performed for data from a phantom containing only relatively small graphite scatters (less than 170 mu), and a similar phantom to which glass spheres 0.5 mm in diameter had been added homogeneously. For lower center frequency narrow-band filters, significantly more high-amplitude occurrences were observed for data from the phantom to which glass spheres had been added. Higher center frequency narrow-band filters gave significantly more high-amplitude occurrences for the phantom containing only small scatters. Similar data analysis was performed for in vivo human liver data from ten normal subjects and five patients with known cirrhosis of the liver. For the cirrhotic and normal livers, data analysis using narrow-band filters of relatively low center frequency resulted in more high- amplitude occurrences for cirrhotic, compared to normal liver; the converse was true for narrow-band filtration at relatively high center frequencies. Determination of mean amplitude following narrow-band filtration with a filter centered at 3.4 MHz was found to be quite repeatable for the normal and cirrhotic liver data; analysis of variance showed the measurement was 94.1% a function of the subject examined, and 5.9% related to the data acquisition session.(ABSTRACT TRUNCATED AT 250 WORDS) | Medical physics | [
{
"affiliation": "",
"forename": "F G",
"identifier": "",
"initials": "FG",
"lastname": "Sommer"
},
{
"affiliation": "",
"forename": "R A",
"identifier": "",
"initials": "RA",
"lastname": "Stern"
},
{
"affiliation": "",
"forename": "P J",
"identifier": "",
"initials": "PJ",
"lastname": "Howes"
},
{
"affiliation": "",
"forename": "H",
"identifier": "",
"initials": "H",
"lastname": "Young"
}
] | 1987 | 3306304 | D006801:Humans; D008099:Liver / Q000033:anatomy & histology* / Q000473:pathology; D008103:Liver Cirrhosis / Q000175:diagnosis*; D012016:Reference Values; D014463:Ultrasonography / Q000379:methods* | D003160:Comparative Study; D016428:Journal Article; D013487:Research Support, U.S. Gov't, P.H.S. | 10.1118/1.596029 | [] | false | eng | Med Phys | 0425746 | 0094-2405 | United States | [
{
"agency": "NCI NIH HHS",
"country": "United States",
"grant_acronym": "CA",
"grant_id": "5 K04 CA00960"
},
{
"agency": "NCI NIH HHS",
"country": "United States",
"grant_acronym": "CA",
"grant_id": "5R01 CA37483"
}
] | "2024-08-13T08:46:10.595575Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Hyperoxaluria. | 13(4) | 242-50 | Urinary oxalate is considered to play a crucial role in the formation of renal stones. In this respect hyperoxaluria constitutes a special problem, mainly because of the specific physicochemical properties of oxalate. The appropriate management of patients with this disorder must be based on a thorough understanding of the absorption, metabolism and excretion of oxalate. Different reasons for high oxalate excretion as well as analytical problems and our current therapeutic possibilities are covered in this review. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "L",
"identifier": "",
"initials": "L",
"lastname": "Larsson"
},
{
"affiliation": "",
"forename": "H G",
"identifier": "",
"initials": "HG",
"lastname": "Tiselius"
}
] | 1987 | 3306316 | D006801:Humans; D006959:Hyperoxaluria / Q000652:urine*; D010070:Oxalates / Q000652:urine | D016428:Journal Article; D016454:Review | D010070:Oxalates | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.596780Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
The hyperuricosuric calcium oxalate stone former. | 13(4) | 251-6 | Hyperuricosuric patients may form uric acid kidney stones and mixed stones containing both calcium oxalate and uric acid. Some of these patients form pure calcium oxalate stones. Explanation of this syndrome was based on the plausibility of epitaxial growth of calcium oxalate on uric acid crystals acting as substrates. In spite of convincing crystallographic consideration, laboratory experiments did not demonstrate any growth of calcium oxalate on uric acid seeds. An amino acid evidently adsorbing on uric acid seeds and attracting calcium ions could act as a mediating agent, thus realizing the potential of the epitaxial growth of calcium oxalate on uric acid crystals. Administration of allopurinol to hyperuricosuric calcium oxalate stone formers reduced the level of uric acid, consequently preventing the creation of uric acid crystals in urine. It should have removed the direct cause for the formation of calcium oxalate stones. Though undoubtedly more effective than placebo, the therapy with allopurinol was not unequivocally successful. Combined therapy using allopurinol and other drugs which were proved to be beneficial for idiopathic calcium oxalate stone formers, seems to give improved results. The use of procedures for evaluating the effect of therapy on risk factors has been started to predict success in individual cases. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Sarig"
}
] | 1987 | 3306317 | D002129:Calcium Oxalate / Q000032:analysis*; D006801:Humans; D013577:Syndrome; D014527:Uric Acid / Q000652:urine*; D014545:Urinary Calculi / Q000032:analysis* / Q000188:drug therapy | D016428:Journal Article; D016454:Review | D002129:Calcium Oxalate; D014527:Uric Acid | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.597473Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Citrate and renal calculi. | 13(4) | 257-66 | Potassium citrate is a new and exciting therapeutic approach which has considerably broadened our capability for the medical control of stone disease. The discussion summarizes the data supporting utility of potassium citrate in the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis ('idiopathic', or secondary to chronic diarrheal syndrome or thiazide therapy) and uric acid lithiasis with or without calcium stones. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "C Y",
"identifier": "",
"initials": "CY",
"lastname": "Pak"
}
] | 1987 | 3306318 | D002951:Citrates / Q000009:adverse effects / Q000627:therapeutic use*; D019343:Citric Acid; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy* | D016428:Journal Article; D016454:Review | D002951:Citrates; D019343:Citric Acid | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.599376Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Glycoprotein calcium oxalate crystal growth inhibitor in urine. | 13(4) | 267-72 | Urine is normally supersaturated with respect to calcium oxalate. Inhibitors of the growth and aggregation of calcium oxalate crystals are present in urine and probably protect against calcium stone formation. These inhibitors are deficient in stone formers. The major inhibitor of calcium oxalate crystal growth is a non-dialyzable, anionic macromolecule. An acidic glycoprotein has been isolated from urine and human kidney tissue culture medium which inhibits calcium oxalate crystal growth in vitro. This glycoprotein crystallization inhibitor has a molecular weight of 14,000 daltons and contains 2-3 residues of gamma-carboxyglutamic acid. The dissociation constant for the calcium oxalate crystal-inhibitor complex is about 10(-7) M. The glycoprotein isolated from the urine of calcium stone formers has a decreased affinity for crystal surface, and a proportionally weaker inhibitory activity; it also lacks gamma-carboxyglutamic acid. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "E M",
"identifier": "",
"initials": "EM",
"lastname": "Worcester"
},
{
"affiliation": "",
"forename": "Y",
"identifier": "",
"initials": "Y",
"lastname": "Nakagawa"
},
{
"affiliation": "",
"forename": "F L",
"identifier": "",
"initials": "FL",
"lastname": "Coe"
}
] | 1987 | 3306319 | D002129:Calcium Oxalate / Q000037:antagonists & inhibitors* / Q000652:urine*; D006023:Glycoproteins / Q000652:urine*; D006801:Humans; D014545:Urinary Calculi / Q000652:urine* | D016428:Journal Article; D016454:Review | D006023:Glycoproteins; C029490:nephrocalcin; D002129:Calcium Oxalate | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.600025Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Glycosaminoglycans as inhibitors of stone formation. | 13(4) | 273-7 | The presence of glycosaminoglycans in the kidney, bladder and urinary tract exerts influence on stone formation through prevention of growth and aggregation. The source of the urinary glycosaminoglycans is contentious with respect to the relative contribution of the kidney and bladder secretions to the overall inhibitory power. Mechanisms have been advanced for the action of glycosaminoglycans, and the active species involved appears dependent upon the degree of sulfation of the molecule. Thus, the ultimate role of glycosaminoglycans as urinary inhibitors of stone formation may well be dictated by the specific nature of the glycosaminoglycan present and its inherent acidic properties. The overall contribution of urinary glycosaminoglycans to protect against urolithiasis however still needs to be evaluated. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "J D",
"identifier": "",
"initials": "JD",
"lastname": "Sallis"
}
] | 1987 | 3306320 | D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D007669:Kidney Calculi / Q000517:prevention & control*; D001744:Urinary Bladder Calculi / Q000517:prevention & control*; D014545:Urinary Calculi / Q000517:prevention & control* | D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't; D016454:Review | D006025:Glycosaminoglycans | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.600631Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
Infection (urease) stones. | 13(4) | 278-85 | Infection-induced stones in man probably form solely as a consequence of urealysis which is catalyzed by the bacterial protein urease. Urease stones composed of struvite and carbonate-apatite may form primarily, or as secondary stones or pre-existent metabolic stones. Struvite stones form and grow rapidly owing to (a) supersaturation of urine with stone forming salts, (b) 'salting out' of poorly soluble organic substances normally dissolved in urine and (c) ammonia-induced destruction of the normally protective urothelial glycosaminoglycan layer. Immature (predominantly organic) matrix stones mature into densely mineralized stones. Curative treatment is possible only by eliminating all of the stone and by eradicating all urinary and parenchymal infection. A variety of operative and pharmaceutical approaches are available. Patient treatment must be individualized inasmuch as some patients are better candidates for one type of treatment than another. | Mineral and electrolyte metabolism | [
{
"affiliation": "",
"forename": "D P",
"identifier": "",
"initials": "DP",
"lastname": "Griffith"
},
{
"affiliation": "",
"forename": "C A",
"identifier": "",
"initials": "CA",
"lastname": "Osborne"
}
] | 1987 | 3306321 | D006801:Humans; D014510:Urease / Q000378:metabolism*; D014545:Urinary Calculi / Q000201:enzymology / Q000453:epidemiology / Q000209:etiology*; D014552:Urinary Tract Infections / Q000150:complications* | D016428:Journal Article; D016454:Review | D014510:Urease | [] | false | eng | Miner Electrolyte Metab | 7802196 | 0378-0392 | Switzerland | [] | "2024-08-13T08:46:10.601488Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Recurrent infantile multifocal periostosis. Description of a case]. | 39(11-12) | 545-7 | Minerva pediatrica | [
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Sangermani"
},
{
"affiliation": "",
"forename": "C A",
"identifier": "",
"initials": "CA",
"lastname": "Morello"
},
{
"affiliation": "",
"forename": "F",
"identifier": "",
"initials": "F",
"lastname": "Lucchini"
},
{
"affiliation": "",
"forename": "L",
"identifier": "",
"initials": "L",
"lastname": "Posani"
},
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Vergnaghi"
}
] | 1987-06-30 | 3306322 | D002648:Child; D005260:Female; D006801:Humans; D006958:Hyperostosis, Cortical, Congenital / Q000175:diagnosis* | D002363:Case Reports; D004740:English Abstract; D016428:Journal Article | [] | false | ita | Periostosi multifocale ricorrente infantile. Descrizione di un caso. | Minerva Pediatr | 0400740 | 0026-4946 | Italy | [] | "2024-08-13T08:46:10.602371Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
[Oxyuriasis in childhood. Epidemiologic considerations and diagnostic methods in a sample of symptomatic subjects]. | 39(9) | 365-9 | Minerva pediatrica | [
{
"affiliation": "",
"forename": "L",
"identifier": "",
"initials": "L",
"lastname": "di Martino"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Pettoello Mantovani"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Polito"
},
{
"affiliation": "",
"forename": "S",
"identifier": "",
"initials": "S",
"lastname": "Guandalini"
}
] | 1987-05-15 | 3306323 | D000005:Abdomen; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004757:Enterobius; D005243:Feces / Q000469:parasitology; D005260:Female; D006801:Humans; D007223:Infant; D007558:Italy; D008297:Male; D008828:Microbiological Techniques; D010123:Oxyuriasis / Q000175:diagnosis* / Q000453:epidemiology; D010146:Pain / Q000209:etiology | D004740:English Abstract; D016428:Journal Article | [] | false | ita | Ossiuriasis in età pediatrica. Considerazioni epidemiologiche e metodiche di diagnosi in un campione di soggetti sintomatici. | Minerva Pediatr | 0400740 | 0026-4946 | Italy | [] | "2024-08-13T08:46:10.603388Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
[Clinical and microbiological effects of a single ultrasonic scaling session in periodontal pockets of different depths]. | 36(5) | 347-53 | Minerva stomatologica | [
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Benigni"
},
{
"affiliation": "",
"forename": "M",
"identifier": "",
"initials": "M",
"lastname": "Paolantonio"
},
{
"affiliation": "",
"forename": "M L",
"identifier": "",
"initials": "ML",
"lastname": "Curcio"
},
{
"affiliation": "",
"forename": "C",
"identifier": "",
"initials": "C",
"lastname": "Di Murro"
},
{
"affiliation": "",
"forename": "L",
"identifier": "",
"initials": "L",
"lastname": "Sebastiani"
}
] | 1987-05 | 3306324 | D000328:Adult; D003728:Dental Calculus / Q000382:microbiology / Q000628:therapy; D003777:Dental Prophylaxis / Q000379:methods*; D012534:Dental Scaling / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000382:microbiology / Q000628:therapy*; D010518:Periodontitis / Q000628:therapy*; D014464:Ultrasonic Therapy | D004740:English Abstract; D016428:Journal Article | [] | false | ita | Effetti clinici e microbiologici di una singola seduta di detartrasi ultrasonica in tasche parodontali di diversa profondità. | Minerva Stomatol | 0421071 | 0026-4970 | Italy | [] | "2024-08-13T08:46:10.605612Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
[Protection of the palate after removal of the fibrous mucosa in free gingival grafts]. | 36(6) | 445-51 | Minerva stomatologica | [
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Urbani"
},
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Franco"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Ragni"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Conti"
}
] | 1987-06 | 3306326 | D001458:Bandages; D003094:Collagen / Q000627:therapeutic use; D004388:Dura Mater / Q000637:transplantation; D005881:Gingiva / Q000637:transplantation*; D006489:Hemostatic Techniques; D006801:Humans; D006472:Oral Hemorrhage / Q000517:prevention & control; D010158:Palatal Obturators; D010159:Palate / Q000601:surgery*; D011183:Postoperative Complications / Q000517:prevention & control; D014014:Tissue Adhesives / Q000627:therapeutic use | D004740:English Abstract; D016428:Journal Article | D014014:Tissue Adhesives; D003094:Collagen | [] | false | ita | Protezione del palato dopo prelievo della fibromucosa negli innesti gengivali liberi. | Minerva Stomatol | 0421071 | 0026-4970 | Italy | [] | "2024-08-13T08:46:10.606476Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Type 1 diabetes mellitus and juvenile periodontopathies]. | 36(5) | 355-9 | Minerva stomatologica | [
{
"affiliation": "",
"forename": "D",
"identifier": "",
"initials": "D",
"lastname": "Crea"
},
{
"affiliation": "",
"forename": "C",
"identifier": "",
"initials": "C",
"lastname": "Lauriello"
},
{
"affiliation": "",
"forename": "A",
"identifier": "",
"initials": "A",
"lastname": "Fusco"
}
] | 1987-05 | 3306325 | D000293:Adolescent; D001786:Blood Glucose / Q000032:analysis; D002648:Child; D003774:Dental Plaque Index; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D010510:Periodontal Diseases / Q000097:blood / Q000209:etiology*; D010512:Periodontal Index | D004740:English Abstract; D016428:Journal Article | D001786:Blood Glucose; D007328:Insulin | [] | false | ita | Diabete mellito tipo I e parodontopatie giovanili. | Minerva Stomatol | 0421071 | 0026-4970 | Italy | [] | "2024-08-13T08:46:10.607292Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
|||||
[Salivary acidity as an index of periodontal disease in pregnancy. A clinical contribution]. | 36(6) | 453-9 | Minerva stomatologica | [
{
"affiliation": "",
"forename": "G F",
"identifier": "",
"initials": "GF",
"lastname": "Devalle"
},
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Marini"
},
{
"affiliation": "",
"forename": "E",
"identifier": "",
"initials": "E",
"lastname": "Berutti"
}
] | 1987-06 | 3306327 | D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008828:Microbiological Techniques; D010510:Periodontal Diseases / Q000175:diagnosis*; D049590:Postpartum Period; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis*; D011263:Pregnancy Trimester, Third; D012463:Saliva / Q000032:analysis* / Q000382:microbiology | D004740:English Abstract; D016428:Journal Article | [] | false | ita | L'acidità salivare come indice della malattia parodontale nella gravidanza. Contributo clinico. | Minerva Stomatol | 0421071 | 0026-4970 | Italy | [] | "2024-08-13T08:46:10.608303Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
[Current indications for the use of the bone denudation technic. Report of a clinical case]. | 36(6) | 461-5 | Minerva stomatologica | [
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Urbani"
},
{
"affiliation": "",
"forename": "G",
"identifier": "",
"initials": "G",
"lastname": "Cavalleri"
},
{
"affiliation": "",
"forename": "P",
"identifier": "",
"initials": "P",
"lastname": "Filippini"
}
] | 1987-06 | 3306328 | D000328:Adult; D000044:Dental Abutments; D003830:Denture, Partial, Fixed; D005260:Female; D005881:Gingiva / Q000637:transplantation; D005889:Gingival Recession / Q000601:surgery; D005890:Gingivectomy / Q000379:methods*; D006801:Humans | D002363:Case Reports; D004740:English Abstract; D016428:Journal Article | [] | false | ita | Attuali indicazioni all'uso della tecnica della denudazione ossea. Osservazione di un caso clinico. | Minerva Stomatol | 0421071 | 0026-4970 | Italy | [] | "2024-08-13T08:46:10.609234Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
Meditation: uses and methods in psychiatric nurse education. | 7(4) | 187-91 | Nurse education today | [
{
"affiliation": "",
"forename": "P",
"identifier": "",
"initials": "P",
"lastname": "Burnard"
}
] | 1987-08 | 3306329 | D006801:Humans; D011568:Psychiatric Nursing / Q000193:education*; D012064:Relaxation Therapy | D016428:Journal Article | 10.1016/0260-6917(87)90026-8 | [] | false | eng | Nurse Educ Today | 8511379 | 0260-6917 | Scotland | [] | "2024-08-13T08:46:10.609938Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
||||||
Tuberous sclerosis. | 5(3) | 351-60 | Tuberous sclerosis is a multisystem disorder characterized by changes primarily involving the skin, eye, and central nervous system. Although the disease often produces mental retardation and seizures, this is not universal, and some patients with tuberous sclerosis lead a relatively normal life. | Neurologic clinics | [
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Hanno"
},
{
"affiliation": "",
"forename": "R",
"identifier": "",
"initials": "R",
"lastname": "Beck"
}
] | 1987-08 | 3306330 | D003937:Diagnosis, Differential; D006801:Humans; D012871:Skin Diseases / Q000175:diagnosis*; D014402:Tuberous Sclerosis / Q000175:diagnosis* | D016428:Journal Article; D016454:Review | [] | false | eng | Neurol Clin | 8219232 | 0733-8619 | United States | [] | "2024-08-13T08:46:10.610647Z" | https://ftp.ncbi.nlm.nih.gov/pubmed/baseline/pubmed24n0110.xml.gz |
Subsets and Splits